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DEVELOPMENT OF QUANTITATIVE BIOANALYTICAL METHODS FOR THE 
MEASUREMENT OF PHARMACEUTICAL ANALYTES VIA HPLC-UV AND 
HPLC-MS/MS 
MELISSA A. McCULLOCH 
 
ABSTRACT 
 
 
 Research in pharmaceutical treatments for illnesses and disease 
processes has rapidly grown in the past decade.  The field is fueled by advances 
in our understanding of the molecular mechanics of the human body, coupled 
with the development of sophisticated scientific instruments which can efficiently 
generate massive amounts of important data.  This has led to an ever-growing 
need for the development of quantitative bioanalytical methods to measure 
pharmaceutical compounds.  
 In this work, the theory behind the analytical processes and instruments 
that make these investigations possible is discussed.  Further, the development 
of two high performance liquid chromatographic (HPLC) methods with both ultra 
violet (UV) spectrometry and mass spectrometry (MS) detection of the 
cannabinoid (CB) antagonists‟ rimonabant and surinabant is presented.  The 
methods developed for the CB antagonists‟ are successfully applied to animal 
studies in clinical and pre-clinical investigations.  Thirdly, preliminary work is 
included which was conducted for the development of two methods to be used in 
the measurement of anti-cancer agents, quinacrine and triapine.   Finally, a 
discussion is presented for the consideration of the challenges and potential 
solutions in the development of an HPLC-MS method for triapine.   
 v 
 
 The theory, experimental designs and results discussed here 
demonstrates how analytical chemistry and instrumentation are used in 
bioanalytical method development.   This research also illustrates how once 
developed, these methods serve to advance the progress in biochemical, 
preclinical and clinical studies.   
 vi 
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CHAPTER I 
 
 
INTRODUCTION TO BIOANALYTICAL METHOD DEVELOPMENT: 
PHARMACEUTICAL COMPOUND EXTRACTION, HIGH PERFORMANCE 
LIQUID CHROMATOGRAPHY AND MASS SPECTROMETRY 
 
 
1.1  Rationale for Method Development 
 
The development of analytical methods to quantitate drug molecules is critical 
to the progress of toxicological, biochemical and clinical studies.  Methods must 
be established and validated to demonstrate robustness, precision and accuracy 
of the ability of the method to determine the amount of drug present in the 
sample of interest.  The ability to ascertain the amount of drug present provides 
the research community with the ability to establish the pharmacokinetics, or how 
the body processes the drug [1], as well as the pharmacodynamics [1], how the 
drug affects the body.   
  2 
Pharmacokinetic parameters are divided into several sections, referred to as 
a LADME scheme [2]:  liberation, absorption, distribution, metabolism and 
excretion.   Liberation refers to the manner which the drug is released from the 
formulation.  Absorption deals with how the drug is introduced to the body.  
Distribution is the dispersion or dissemination of the drug within the bodily fluids 
and tissues.  Metabolism describes the transformation of the original drug into 
metabolites.  Excretion refers to how the drug is removed from the body.   
Pharmacodynamics consists of three principle components [3]:  the desired 
affects of the drug, undesired affects of the drug and the therapeutic window of 
the drug.   Desired affects of a drug can be caused by a variety of biochemical 
processes, including: chemical reactions, interaction with proteins, interaction 
with ion channels and ligand binding.  There are also many situations which 
produce undesirable effects of a drug, including:  mutagenic or carcinogenic 
cellular response, as well as, inducing cellular damage which can lead to chronic 
biological and physical abnormalities.  Finally, the therapeutic window can be 
though of as the effective dosing, or the dosing amount that provides more 
desirable effects versus undesirable effects.   
In order to study the behavior of a drug within an animal body, it is necessary 
to establish bioanalytical methods.  There are several important considerations 
for the methods being developed:  cost, an effort should be made to favor 
consumables which are the least expensive; time, the total sample preparation 
and run time should be kept to a minimum to enable high throughput of the 
  3 
method; simplicity and transferability, the method developed should avoid over 
complication.   
 
1.2 Extraction of Pharmaceutical Compounds from Biological Matrices 
 
1.2.1  Introduction 
 
Bioanalytical methods allow the detection of small amounts of a drug within a 
complex biological matrix, commonly plasma, urine, saliva or tissue.  The 
biological materials are composed of a vast array of compounds, with varying 
chemistries.  In order to detect trace amounts of pharmaceutical compounds 
present in these materials, the compounds must be removed from the remaining 
compounds in the sample.   
The first step in the development of a method is the extraction or removal of 
the compound from the biological matrix.  The matrix of blood will be discussed 
here.  Blood is composed of red blood cells, approximately 45% by volume, 
which are suspended in plasma fluid (55% by volume).  Plasma is approximately 
92% water and 8% plasma proteins and other compounds such as minerals, 
glucose, carbon dioxide, hormones and pharmaceutical compounds [4]. 
Prior to analytical treatment, whole blood undergoes several pretreatment 
steps to separate the plasma from the red blood cells.  First and anticoagulant is 
added to whole blood to prevent clotting.  Secondly, the red blood cells are 
separate from the plasma via centrifugation.  In addition to the red blood cells, 
  4 
many plasma proteins will be removed from the plasma during this step.  The 
protein in highest abundance remaining in the plasma is albumin.   In addition to 
albumin, the plasma matrix consists of many compounds, including other 
proteins, minerals, electrolytes (salts), glucose, carbon dioxide, hormones and 
pharmaceutical compounds [5].       
Although many potentially interfering substances have been removed from 
the whole blood, the reduction of matrix components remaining in the plasma will 
improve the sensitivity of developed method for the compound of interest.  
Further, salts, proteins, and various chemical species remaining can create 
contamination as well as negatively affect the precision and accuracy of the 
method ability to detect the pharmaceutical compound.  There are many popular 
suitable chromatographic methods which are a good choice for removing the 
pharmaceutical compound from the biological matrix.  Common types of 
chromatography used for this purpose include:  liquid/liquid extraction, protein 
precipitation, and solid phase extraction.     
 
1.2.2  Liquid Liquid Extraction (LLE) 
 
LLE  is based on partitioning of compound into two separate liquids.  LLE 
works by exploiting the solubility of an compound in two immiscible liquids, 
generally an aqueous and an organic.  Organic solvents with low polarity are 
generally immiscible with water.  For instance, toluene, diethyl ether and hexane 
not miscible and less dense than water, forming a partition that floats on top of 
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the aqueous phase.  Chloroform and methylene chloride are immiscible and 
more dense than water, forming a partition underneath the aqueous phase.    
The distribution or partitioning of an compound (solute) between the two 
phases in LLE can be represented by the following equilibrium equation, 
equation (1) [6]: 
  
 
Therefore, the equation describing the partition coefficient, the ratio of species in 
each respective phase can be written as equation (2) [6]: 
 
Kp = [Sorganic] / [Saqueous] 
Evidenced by equations 1 and 2, the amount of analyte in each phase is an 
equilibrium process and for any Kp value, there will remain an amount of analyte 
in the aqueous phase.  The equation describing the amount of analyte remaining 
in the aqueous phase after n injections is given in equation (3) [6]: 
 
qn = [V2/(V2+KpV1)]
n 
 
where q is the fraction of S remaining in the aqueous phase, V1 is the volume of 
the organic phase,   V2 is the volume of aqueous phase and Kp is the partition 
coefficient.   In order to achieve quantitation removal of an analyte, several 
extractions are often required.   
Solute (aqueous phase)  
 
Solute (organic phase)  
 
(1) 
(2) 
(3) 
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Figure 1.1,  Representation of LLE 
 
aqueous 
organic 
vortex 
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1.2.3  Protein Precipitation  
 
Protein precipitation bears many similarities to LLE.  Consider a plasma 
sample which contains an analyte to be extracted, in addition to the analyte; 
there are countless proteins, salts, metals and other compounds present in the 
plasma sample.  Proteins contain both hydrophilic and hydrophobic amino acid 
residues.  When dissolved in water, the hydrophilic amino acids are oriented so 
as to interact with the polar, aqueous phase.  In the case of hydrophobic amino 
acids, they interact with various ions in the solution to stabilize the proteins 
solubility in the aqueous phase [7].   
There are two types of forces acting upon a protein molecule in an aqueous 
solution, repulsive electrostatic force and attractive electrostatic force.  Repulsive 
electrostatic forces are demonstrated in figure 1.2.  Further detail describing the 
solvation (or hydration) layer of proteins is contained in figure 1.3.   
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Figure 1.2, Depiction of electrostatic forces present in protein solutions 
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Figure 1.3, Ion distribution in the hydration layer of a protein solution 
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The repulsive forces between proteins prevent the proteins from interacting 
with another and promote the dissolution of the proteins in the aqueous solvent.  
This phenomenon occurs because counter ions migrate to the surface of the 
protein molecules and form a rigid barrier, effectively neutralizing the surface of a 
charged molecule.  Beyond the rigid counter ion barrier, ions continue to migrate 
in increasingly lower concentrations.  This loose, charged barrier around the 
proteins, allow the protein molecules to remain dissolved in solution while, at the 
same time, prevent the aggregation of protein molecules into clusters.  Water     
itself can serve to generate the barrier surrounding the proteins [7].   
 Attractive electrostatic forces exist due to induced or permanent dipoles of             
protein molecules.  A general illustration of attractive electrostatic forces is 
contained in figure 1.4.  One example of an attractive electrostatic force between 
proteins would be the interaction of acidic residues on one protein with basic 
residues of another.  The solvation of the proteins by the hydration layer serves 
to disrupt the attractive forces between proteins [7].   
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Figure 1.4, Hydration layer disruption caused by protein-protein 
interactions   
 
  12 
  
 Protein precipitation occurs in several steps:  addition of precipitating 
agent, mixing and precipitate formation.  Commonly an organic solvent such as 
acetonitrile or methanol is used as the precipitation agent.  Upon the addition of 
these solvents, the solution looses stability.  The unstable solution will cause 
denaturation of proteins and the mixing will cause the denatured proteins to 
aggregate and to precipitate from the plasma solution.  Based on the size and 
weight of the precipitated proteins, they begin fall to the bottom of the extraction 
vessel.  Further, many salts are not soluble in the organic solvents and therefore 
also precipitate out of the plasma solution.  The precipitated proteins can further 
be separated from the extraction solvent via centrifugation.   Once centrifuged, 
the organic supernatant can be evaporated and thereafter reconstituted in order 
to control the concentration.    
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Figure 1.5, Protein precipitation procedure   
 
Plasma 
  
 200 μL 
50 μL AA 
10 μL IS 
10 μL Std 
1 mL ACN 
 Vortex 
Supernatant 
Centrifuge 
15 min 
10,000 rpm   
 
 Vortex  
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1.2.4  Solid Phase Extraction (SPE) 
 
SPE is a widely used chromatographic method to separate an analyte from a 
complex matrix.  In SPE, a column is packed with a stationary phase which will 
retain the analyte of interest.  Commonly, the stationary phase, or sorbent is 
composed of a carbon based packing material as C18 and C8.  There are 
generally four steps in SPE, sorbent conditioning, sample loading, rinsing and 
sample elution [8].  A block diagram demonstrating a general SPE process is 
contained in figure 1.6.  
Step one is to activate the sorbant by rinsing with an organic solvent in order 
to wet the stationary phase.   The hydrophobic packing is dry initially and the 
ligands are all collapsed. Organic phase extends the ligands and prepares them 
for interaction with the analyte [8]. 
   Step two of SPE is the sample loading phase.  A solution containing the 
sample, as well as, any contaminants or interfering substances, is introduced 
onto the stationary phase.  The stationary phase will interact with the analyte 
molecules, retaining them until step four.   
  15 
 
 
 
 
Figure 1.6, SPE procedure 
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 Step three of SPE is a washing step which aids in the removal of 
contaminants and interfering compounds.  This step is conducted again with the 
solvent composition of the sample matrix.   During this step, the analyte will be 
bound by the stationary phase and will not be released by the column.   
 Finally, in step four of SPE, an elution solvent is introduced to the column.  
The elution solvent will have distinctly different properties than the solvent used 
for the previous three steps.  For example, considering a hydrophobic 
pharmaceutical compound:  should the sample be loaded in an aqueous plasma 
solution, an organic solvent such as acetonitrile may be used to elute the 
compound.  As in LLE, the elution solution collected may be evaporated in order 
to control the concentration.   
 
1.3 High Performance Liquid Chromatography (HPLC) 
 
1.3.1  Introduction 
 
HPLC is a cornerstone of bioanalytical chemistry which began development in 
the 1970‟s.  HPLC can be used to separate, identify and quantitate and any 
compound which can be dissolved in a liquid.  HPLC is not bound by sample 
volatility or thermal stability, is conducted at room temperature, is able to be 
automated, provides ease of use, and generates powerful data.   
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Many forms of HPLC exist, including:  normal phase, reverse phase, ion 
exchange, size exclusion and bioaffinity, to name a few.   It is important to 
differentiate between normal and reverse phase chromatography.  In the case of 
normal phase, the compound of interest has a polar, or hydrophilic chemical 
composition.  Chromatographic conditions for normal phase would utilize a polar, 
hydrophilic analytical column and mobile phase composition.  The vast majority 
of pharmaceutical compounds investigated are either non-polar, hydrophobic or 
both.  Due to the chemical nature of pharmaceutical compounds, reverse phase 
HPLC is typically used.  In reverse phase HPLC, the hydrophobic interactions 
between the analyte and the column are manipulated and the mobile phase 
typically has a strong organic component [9].    
The work described here deals exclusively with reverse phase HPLC, the 
most popular type currently used in bioanalytical method development for drug 
compounds, all references to HPLC will be in respect to reverse phase HPLC.  
There are five (5) principle components to an HPLC system, the mobile phase, 
pump, injector, column and detector.  A flow diagram of an HPLC system is 
contained in figure 1.7.  A in depth discussion of each component follows.   
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Figure 1.7, Flow diagram of HPLC setup 
mobile 
phase 
pump injector column 
detector 
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1.3.2  Column Selection 
 
In today‟s entrepreneur driven society, there are countless manufacturers of 
columns to be used in bioanalytical method development for the detection of 
pharmaceutical analytes.  The discussion that follows will consider only columns 
suitable for reverse phase chromatographic separations.   Within the different 
manufactures of columns, there exists a broad array of column chemistries.  The 
most widely used columns utilize carbon based chemistry in design, for example 
C18, C8 and C4.  A successful column will allow for suitable resolution of the 
analytes of interest, low backpressure generation, minimal solvent consumption 
and short analysis times.  
In respect to column choice the most important phenomenon to avoid is band 
broadening.   Band broadening lowers the number of theoretical plates in a 
column thereby reduces the separation power of a column.  There are three 
factors which contribute to band broadening:  longitudal diffusion, resistance to 
mass transfer across phases (stationary and mobile), and eddy diffusion which is 
caused by mobile phase factors.   
Longitudal diffusion is diffusion of the sample in a direction parallel to the 
sample flow.   
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Figure 1.8, Figural depiction of longitudal diffusion   
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As evidenced in figure 1.8., the longer a solute remains in a column the more 
a sample diffuses and the broader the peak shape becomes.  The length of time 
a solute remains in a column has an inverse relationship to the mobile phase flow 
rate and therefore the longitudal diffusion is also inversely proportional to the 
mobile phase flow rate.  The equation relating the longitudal diffusion (σL
2) to the 
length of the column (L) is given in equation x., where Dm represents the 
diffusivity of the solute in the mobile phase u is the linear velocity of mobile phase 
and γ is a constant that depends of the column packing material [10]. 
 
σL
2  = (2DmL γ)  / u 
 
As evidenced in equation 4, band broadening due to linear diffusion can be 
reduced by manipulating the mobile phase flow rate and the column length.   
 A second factor affecting band broadening is the resistance to mass 
transfer across the boundaries of both the stationary and mobile phase [11].  
Figure x is a simple graphical depiction of how mass transfer can cause band 
broadening.  
(4) 
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Figure 1.9, Mass transfer due to (A) resistance in the mobile phase and (B) 
resistance in the stationary phase 
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In figure 1.9(A) it is evident that in the beginning, all analyte molecules occupy 
a small horizontal space.  During this time, some of the analyte molecules are 
transferred from the mobile phase to the stationary phase, this process is 
dictated by the spatial proximity of the molecules to the stationary phase.  It will 
take longer for molecules that are further a longer time to interact with the 
stationary phase.   This time results in band broadening.  The same scenario can 
be considered for the molecule bound to the stationary phase as depicted in 
figure 1.9(B).  While the molecules initially are confined to a narrow horizontal 
space, it will require time for the molecules a greater vertical distance from the 
boundary of the phase to migrate to that surface and interact.  Again, the 
resistance to mass transfer causes band broadening.   
 The last phenomenon that causes band broadening is eddy diffusion [11].  
Eddy diffusion is the uneven flow distribution of a mobile phase through a 
stationary phase.  This form of diffusion is not well described using a 
mathematical equation.   
  Besides the considerations discussed regarding band broadening and the 
various diffusions that cause it, there are other factors to consider in column 
choice.   Overall the parameters are column length, particle size, column 
diameter (internal diameter), and pore size [12, 13]. 
 In respect to column length, the longer a column, the higher the resolution 
power.  However, as column length increases, the backpressure increases which 
can be unpractical for many HPLC systems.  Generally for reverse phase HPLC 
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analysis of pharmaceutical analytes, columns under 5cm will provide suitable 
resolving power with limited backpressures. 
 The smallest particle size practical should be chosen for column material.  
Currently, standard sizes are 5μm with the smallest size available being 2μm.  
The smaller the particle size, the more theoretical plates per unit length of 
column, which is a desirable feature.  Additionally, small particle sizes allow for 
faster column equilibration with mobile phase as well as, faster analysis times.   
 Common column internal diameters are 4.0-4.6 mm.  In this range of 
internal diameters, the columns can withstand flow rates in the range of 1.0 1.25 
mL/min.   Narrow bore columns are available with internal diameters in the range 
of 2.0 to 3.0 mm.  These columns can withstand flow rates in the range of 0.2 to 
0.6 mL/min.  The narrow bore columns are advantageous because their use 
reduces solvent consumption as well as, improves sensitivity.   
 In respect to pore size, the smaller the pore size, the larger the surface 
area and therefore the greater carbon loading of the column.  In the case of 
pharmaceutical analytes, the optimum pore size is in the range of 80-150 Å.   
 In general, for reverse phase HPLC analysis of pharmaceutical analytes, a 
carbon based column will be a good choice.   A carbon based column is 
composed of silica molecules which are bonded to a carbon chain.  The length of 
the carbon chain typically ranges from C4 to C18.  As the carbon chain length 
increases, the hydrophobicity of the stationary phase also increases.   A common 
defect of carbon columns is related to unreacted silanol groups in the stationary 
phase.  This defect is remedied via a process called endcapping where the 
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unreacted silanol groups are reacted through various chemical processes.    
Each manufacture has unique, proprietary endcapping techniques.    The 
process of endcapping reduces the possibility of undesired, secondary reactions 
between analytes and the stationary phase.  Finally, carbon based columns allow 
for the use of a wide range of mobile phases; including water, acetonitrile and 
methanol; as well as a wide pH range.   
 
1.3.3.  Mobile Phase Selection 
 
The selection of a mobile phase is multifaceted:  the solvent must be able to 
elute the analyte with sufficient resolution, the resolution time of the analyte 
should be low enough to allow for highthroughput, the use of additives such as 
buffers and acids should be kept to a minimum and the organic component 
should be chosen with cost in mind.   There are endless possibilities for mobile 
phase compositions; it is helpful to consider two (2) primary features affected by 
formulation of mobile phase:  solvent polarity and solvent selectivity [11, 12].  The 
equation describing the relationship between solvent polarity and solvent 
selectivity is contained in equation 5. 
 
Rs = √N/4 (α-1/α) (k
‟/1+k‟) 
 
(5) 
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In equation 5, the term (α-1/α) represents the solvent selectivity factor and the 
(k‟/1+k‟) is the solvent polarity term, √N/4 is the column factor, and Rs is the 
resolution value.  Table I. lists the properties of several common solvents.   
The relationship between the polarity index of a solvent and the polarity term 
given in equation 4 for a reverse phase system is given by equation 6. 
 
k„2/ k
„
1 = 10 ^ [(P
‟
2 – P
‟
1)/2] 
 
The values of k‟  are initial and final values and are related to the retention time tr 
of an analyte and the retention time of the unretained solvent (solvent front) t0 
given by equation 7. 
 
k‟ = tr – t0/t0
 
(6) 
(7) 
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Table I  Properties of common solvents   
 
Solvent Refractive 
Index  (25
◦
C) 
Viscosity, cP Boiling 
Point, 
◦
C 
Polarity 
Index, P
’
 
Elutent 
Strength, є
0
 
water 1.333 0.89 100 10.2 Large 
acetonitrile 1.341 0.34 82 5.8 0.65 
methanol 1.326 0.54 65 5.1 0.95 
n-Hexance 1.372 0.30 69 0.1 0.01 
toluene 1.494 0.55 110 2.4 0.29 
ethyl acetate 1.370 0.43 77 4.4 0.58 
chloroform 1.443 0.53 61 4.1 0.40 
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A successful mobile phase composition should aim for a k‟ value between 2 
and 5 for a two component system and for a k‟ between 0.5 and 20 for a multiple 
component system [14}.  After the solvent composition of mobile phase is 
optimized fro k‟, generally the analytes will be suitably resolved.  In the case that 
the retention times of the analytes continue to overlap, α, the selectivity factor 
can be manipulated.  The typical approach to optimizing the selectivity factor is to 
change the chemical composition of the mobile phase while holding the k‟ 
constant.  Equation 8 [14] demonstrates the approach to changing the selectivity 
of a mobile phase without having an effect on the k‟ for a reverse phase system. 
 
Фc = [[Фb (Pw –Pb)]/ (Pw –Pc)] 
 
In equation 7, there are three solvents to consider: W, water; B, the organic 
component that is being changed and; C, the organic component that is replacing 
B.   In this equation, Фc represent the %volume of solvent C;  Фb is the volume of 
the organic component B; and  Pw, Pb, and Pc represent the polarity indexes of 
water, solvent B and solvent C, respectively.   
 As evidenced by the preceding discussion, through the use of a handful of 
simple equations, it is possible to both predict and adjust the chromatography 
results based upon mobile phase composition.  
(8) 
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1.3.4  Pump 
 
The goal of a pump is to provide the most constant flow possible of mobile 
phase to the column.  Due to the small particle sizes of column packing material, 
there is a great resistance to the flow being delivered to the system.   The “HP” of 
HPLC originally represented “high pressure” because of the high pressure which 
is generated during this process.  There are several types of high pressure 
pumps which can be coupled to HPLC systems.   Due to the vast number of 
pump types available, a summary list of pump types and their characteristics is 
contained in Table II. [14]. 
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Table II., Performance characteristics of different types of pumps 
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1.3.5  Injector 
 
With respect to injectors, there are four primary considerations:  the 
sample should be introduced to the column via a narrow plug; the injector should 
be easy to use; the results should be reproducible from injection to injection and; 
the injector should be able to operate at a high back pressure.   
Typical sample loop sizes range from 5 to 50 μL.  In order to avoid problems 
related to dilution, the sample loop should be overfilled by at least three loop 
volumes.   
 Most modern HPLC instruments are coupled with automatic sample 
injectors, or autosamplers.  The injections are controlled by a computer and 
robotic instrumental components which diminishes most error introduced during 
the injection process.    
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Figure 1.10, Example of injector port 
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1.3.6 Detector 
 
A vast array of detectors can be coupled to HPLC systems.  A summary of 
popular detectors and their detection limits is contained in Table III. [14].  The 
research presented here focuses on two types of detectors, the ultraviolet 
detector and mass spectrometer, both of which are described in great detail in 
future sections.   
  34 
 
 
Table III.  Detection limits achievable using various detectors 
 
 
 
 
 
 
 
 
 
1000Fourier transform infared
0.1-1Mass spectrometry
0.3Conductivity
0.001-0.01Fluorescence
0.01-1Electrochemical
0.1-1Evaporative light scattering
100-1000Refractive index
0.1-1Ultraviolet
~ Limit of detection (ng)Detector
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1.4  Ultraviolet (UV) Spectroscopic Detectors 
 
1.4.1  Introduction 
 
UV spectroscopic detectors are one of the most widely used detectors 
coupled to HPLC systems.  These detectors offer ease of use, are available for 
relatively low cost, allow for excellent linearity and provide sensitivity at a level 
suitable for a wide range of applications.  The principle limitation of the UV 
detector is the requirement that the analyte absorb light in the range of  200 – 
350 Å.   This range includes all substances that have at least one double bond as 
well as any substance possessing non-bonded electrons, this group consists of 
all aromatic compounds, and substances containing CO, CS, N=O groups.  As 
can be imagined, most pharmaceutical analytes belong to the group of 
compounds which will absorb light in the range required to use the UV detector.   
 
1.4.2  Beer-Lambert Law 
 
The Lambert law states that the absorption of light is directly proportional to 
the path length traveled.   Beer‟s law states the relationship between the 
absorption of light and the concentration of analyte.  Together, the Beer-Lambert 
law dictates the results afforded in UV spectroscopy.  The equation for the Beer-
Lambert law is given in equation 10.   
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A = ξ  l C 
Where A represents absorption, ξ is the molar absorptivity, a constant, l is the 
path length that the light travels, and C is the concentration of analyte.   
 
1.4.3  Types of UV Detectors 
 
There are two types of UV detectors, fixed wavelength and multiple 
wavelength detectors [15, 16].  Fixed wavelength detectors operate on a single 
wavelength of light that is generated from a specific type of lamp.  These lamps 
can be mercury (254 nm), cadmium (225 nm), and zinc (214 nm).  It is important 
to note that while these lamps generate the majority of light at the wavelengths 
listed, there is a range of wavelengths emitted,  in order to achieve true 
monochromatic light, a filter would be required.   
(10) 
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Figure 1.11, Fixed wavelength UV detector 
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A multi wavelength detector emits light over a broad range of wavelengths.  
Within the category of multi wavelength detectors, there are two types: the 
dispersive detector and the diode array detector.  The dispersive detector 
monitors the elutent at a single wavelength while the diode array examines the 
elutent over a wide range of wavelengths.   
Figure 1.12 illustrates a dispersive detector.  In this detector light is 
generated from either a deuterium or xenon lamp and is focused by a curved 
mirror onto a diffraction grating.  The light is dispersed and refocused onto a 
plane mirror, the angle of tilt of the mirror is able to control the wavelength of light 
emitted which then travels through the sample cell and column elutent.  
Commonly a wavelength is chosen based on a range of wavelengths that a 
particular analyte is known to absorb.   
  39 
  
 
 
 
 
 
Figure 1.12, Multiple wavelength UV detector   
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Diode array detectors also use deuterium or xenon lamps, however, the path 
that light takes differs greatly from the dispersive detector.  The light generated 
by the lamp passes through a lens system and is then directed through the flow 
cell, permitting light of all wavelengths to pass through the column elutent and 
onto a holographic grating.  Light then travels to a photo diode array which can 
contain a large amount of diodes.  Each diode is regularly sampled and a 
computer reports the output.  Once the spectra is finished being recorded, it is 
possible to go back and review the data generated from any particular diode, 
depending on the wavelength(s) of interest.   
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Figure 1.13, Diode array detector   
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1.4.4  Concluding Remarks  
 
As discussed, UV detectors are suitable for a wide range of applications.  The 
instrumental setup provides an ease of use that is remarkable when the power of 
data generated is to be considered.  The linear range afforded by either the fixed 
or multi wavelength detector is in the range of 5 x 10-8  to 5 x 10-4 g/mL.   Further, 
an average HPLC with UV detector can be purchased for under $100,000, which 
puts these instruments within the financial grasp of many researchers.   
 
1.5  Mass Spectrometric (MS) Detectors 
 
1.5.1  Introduction 
 
Mass spectrometers are arguably the most powerful instruments available 
to the analytical chemist today.  The data generated via these instruments is able 
to both qualitate and quantitate chemical species, provide structural elucidation, 
as well as elemental analysis for compounds.  There are many types of mass 
spectrometers including: triple quadrapole (QQQ), ion trap (IT) and time of flight 
(TOF).   
 Mass spectrometers work by detecting a signal based on a mass to 
charge (m/z) ratio for ionized compounds.  A mass spectrum is a graph of the 
intensity of ions versus the mass to charge ratio.   
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 There are four principle steps carried out by the components of a mass 
spectrometer:  ionization, acceleration, deflection and detection [17].   An ion 
source causes the analyte compounds to enter the gas phase.  A mass analyzer 
is equipped with sophisticated electronics which accelerate and deflect or focus 
the ions.  Finally, a detector measures the ion signal produced from the 
preceding components.   
  
1.5.2  Ion sources 
 
Ion sources vary widely and are dependant upon the type of material which 
needs to be ionized.  The ion source can be viewed as the most important of the 
mass spectrometers components, without successful ionization there will be no 
analyte to be focused in the mass analyzer and thereafter detected.    Some of 
the many types of sources include:  electron ionization (EI), chemical ionization 
(CI), atmospheric pressure ionization (API), and electrospray ionization (ESI).  A 
brief discussion of the theory involved in each of the four ionization methods 
mentioned follows, however, this work described here focuses primarily on ESI, 
which will be considered in more detail.   
In electron ionization (EI) a beam of electrons passes through an electric field 
and gains energy.  The accelerated electrons interact with the analyte molecules 
causing the analytes to form ions and ion fragments.  Representative reactions 
are contained in equations 11 and 12.  In equation 11, a neutral analyte forms a 
radical cation.  In some situations the interaction with accelerated electrons 
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causes the ion formed to possess such an amount of energy that it is further 
fragmented, which is depicted in equation 12 [17].   
 
 
e- + M → M•+ + 2e- 
 
e- + M → M•+ + 2e-+ A+ +B+, etc. 
 
In these equations x and x, e-
 
represents an electron, M represents the analyte 
and A+ and B+  are the fragments produced from M•+.   
 Chemical ionization (CI) is quite similar to EI, the first ionization step being 
the same.  However, the steps following the initial ionization are different.  
Chemical ionization uses a flow of reactive gas, often methane (CH4) to react 
with an electron beam.   In CI, the analyte (M) is present in relatively small 
amounts in the collision gas, therefore the electrons interact more strongly with 
the gas molecules (R) which are in higher concentration.  The electron interaction 
creates a high concentration of gas ions (R•+), it is the gas ions that then interact 
with the analytes (M).  A representative equation demonstrating the ionization 
process in CI is contained in equation 13 [17].    
 
R → R+ → RH+ + M → MH+ + R 
 
(11) 
(12) 
(13) 
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CI can be thought of as a more soft ionization process compared with EI and is 
often favored because often EI generates all fragments, resulting in the absence 
of analyte ions.   
 Atmospheric pressure ionization (API) differs primarily from CI and EI in 
that with both CI and EI, the ionization process occurred in the gas phase, 
therefore any compound to be analyzed must first be vaporized.  Contrary to CI 
and EI, API is a method of ionizing nonvolatile species.   Although API differs 
from CI, there are many similarities and API is sometimes referred to APCI, or CI 
conducted under atmospheric pressure.  A diagram which illustrates API is 
contained in figure 1.14 [19].   
     In API the analyte and solvent flow from a discharge needle and are exposed 
to a nebulizing gas at atmospheric pressure.  Heat is applied to the liquid flow via 
a drying gas and further aids in the vaporization of the solvent and analyte 
molecules.  Within the heated source is a corona discharge needle which applies 
a voltage, ionizing the solvent molecules.  The ionized solvent molecules then act 
similar to the process of CI, where collisions and charge transfers generate 
ionized analytes.  API or APCI, is often favored in high molecular weight, 
biological molecules such as proteins, oliogosaccharides, and oligionucleotides.   
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Figure 1.14, API ionization  
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The final ionization method to be discussed is by far the most commonly used 
and the most widely applicable.  Electrospray ionization (ESI) is similar to API in 
that a liquid is subjected ionization at atmospheric pressures, however in ESI, the 
actual ionization is not a chemical ionization procedure [18].    
In ESI, a solution is pumped through a capillary at a low flow rate, the optimal 
flow rate is a design feature of each instrument, in the work presented here it is 
should be less than 100 μL/min.  The capillary is subjected to a high voltage, and 
can be positive or negative, depending on the analyte of interest.  The voltage 
applied to this capillary facilitates the formation of an electrical gradient and 
promotes charge separation; the result is the droplets emerge from the tip of the 
capillary in a formation known as a Taylor cone.  The charged droplets emerge 
from the Taylor cone formation and travel towards the entrance to the mass 
spectrometer.   
Figure x.   
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Figure 1.15, ESI ionization  
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Once droplets have emerged from the tip of the capillary, they are ionized 
through a process which has been described with various theories.  The coloumb 
fission mechanism asserts that as the solvent evaporates, there is an increase in 
charge density around the droplets which causes large droplets to break into 
smaller droplets, eventually resulting in singly charged ions.  A second 
mechanism of ionization, ion evaporation, states that the increased charge 
density caused by solvent evaporation causes an electric repulsion that provides 
the force to overcome the surface tension of the droplet and ions are released.   
ESI is a suitable ionization technique for the analysis of a wide range of 
compounds.  The relatively “soft” ionization process deems it a method of choice 
for high molecular weight biological compounds as well as, small drug molecules.  
As mentioned, the majority of pharmaceutical compounds tend to be non polar 
and ESI is generally more successful with non-polar compounds versus polar 
species.   
In conclusion, it is important to note that during ESI-MS instrumental 
development, the pursuit of lower detection limits and increased sensitivity 
focuses on the design of the ESI source to improve ion transmission.  Further, 
instrumental parameter which is critical to successful ion transmission is the flow 
rate of liquid entering the ion source.    
 
1.5.3  Mass Analyzers 
 
The mass analysis component of a mass spectrometer serves to sort  
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through the ions produced in the ion source so that only the ions of a specific 
mass or mass range are detected.  There are several types of mass analyzers 
available including:  single quadrapole, triple quadrapole, quadrapole ion trap, 
time of flight and magnetic sector.  A table highlighting the characteristics of 
several types of mass analyzers is contained in table IV.  [20]. The work 
presented here focuses on two types of analyzer, the triple quadrapole (QQQ) 
and the quadrapole ion trap (IT), the discussion presented will be limited to these 
types of analyzer.   
Both the QQQ and the IT possess a quadrapole design.  The quadrapole 
consists of four metal rods, aligned parallel to one another.  Each pair of 
opposing metal rods is connected electronically and a radio frequency (RF) 
voltage is applied between them.  A direct current voltage is then applied, 
superimposed upon the RF voltage.  The currents applied to the metal rods 
generate an electric which focuses the ions based on their mass to charge (m/z) 
ratio.  As evidenced in figure x. only ions of a specific m/z ratio will be resonant 
and permitted to pass through the quadrapole.  The remaining ions are deflected 
out of the quadrapole and therefore, not detected [17].   
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Table IV., Properties of various mass analyzers 
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 In the case of a QQQ mass analyzer, three quadrapole are arranged in 
sequence.  As depicted in figure 1.17, the QQQ design is composed of three 
quadrapoles arranged in series.  The first (Q1) and third (Q3) quadrapoles serve 
as mass filters, with the second (Q2) acting as a collision cell.   In Q1, voltages 
are applied to select for the m/z ratio or range of m/z ratio of the analyte of 
interest, the remaining m/z ratios are deflected and do not pass to the Q2.  The 
ions which pass from Q1 to Q2 are commonly referred to as parent ions.   
In the Q2, or collision cell, a collision gas is introduced to the analytes that 
have entered from Q1.  The collision cell does not have mass filtering capacity; 
an RF only voltage is applied here to essentially “hold” the ions of a selected m/z 
ratio so that they can undergo fragmentation.  Fragmentation is carried out using 
Ar, N2 or He gas being introduced causing the ions to undergo collision induced 
dissociation.  The pressure of collision gas can be controlled to provide optimal 
fragmentation.   
Once the ions have been fragmented, they travel to Q3 which operates as a 
second mass filter.  The Q3 then scans a range of m/z ratios so as to allow a 
range of the fragments produced in Q2 to pass to the detector.  This process is 
considered MS2 and is referred to as tandem mass spectrometry or MS/MS.  
The ions which are selected for in Q3 and subsequently detected are typically 
referred to as daughter ions [17].    
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 Figure 1.16, Quadrapole design 
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Figure 1.17, Schematic of a QQQ design 
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QQQ-MS/MS is currently the most popular instrument used in the 
development of quantitative bioanalytical methods for pharmaceutical analytes.  
However, the usefulness and power of this instrument is not limited to the 
development of such methods.  The strength of this instrument rests in the 
generation of daughter ions.  The data provided through the m/z ratio of daughter 
ions has several applications.  First, the m/z ratios can be used to offer an added 
degree of specificity to a bioanalytical method.  Secondly, the fragmentation 
pattern can be looked at like puzzle pieces, put together; they can provide 
structural information regarding an unknown compound.  Third, the fragmentation 
pattern generated can be treated as a fingerprint for identification of complex 
biological molecules.   
The second mass analyzed to be discussed is an linear ion trap (IT).  There 
design of the IT is quite similar to the QQQ, in fact the IT also employs a 
quadrapole in its design.   However, the electronics applied to the quadrapole in 
an IT differ from the QQQ.   
In an IT mass analyzer, ions generated at the source are accelerated into the 
analyzer by a difference in voltage applied across a glass capillary with metal 
endcaps.  The ions exiting the capillary are focused by a skimmer which has an 
electrical charge applied that does not permit ions that fall outside m/z range of 
interest to pass to the octapoles, mass filters.  The octapoles are designed much 
the same as quadrapoles discussed previously, and they act to guide the ions 
along the path of the instrument to the ion trap.   
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Figure 1.18, IT-MS   
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The ion trap component of the linear IT mass analyzer is a quadrapole 
equipped with electrode end caps on both sides.  This component is able to hold 
ions within it boundaries due to an RF frequency being applied to the rods of the 
quadrapole by the endcapping electrodes.  The voltages applied act as gate 
doors: opening on one side to allow the entrance and accumulation of ions for 
some time; closing and trapping the ions; then re-opening to allow the ions (or 
ion fragments) to exit the trap and travel to the detector.   
 The primary strength of IT mass analyzers is the ability of the trap to hold 
a single ion species within the trap, apply a collision gas, and for the ions to 
undergo collision induced dissociation.  This isolation - collision process, or 
tandem MS, can be repeated many times, very rapidly without the need for 
multiple analyzers.  The fragments, or daughters generated from MSn steps is 
extremely valuable for structure elucidation.  Another popular analysis made 
possible by the data generated in MSn is the identification of proteins using the 
fingerprint afforded by the daughter fragments [20].   
 It is useful to compare the features, or lack of between the QQQ and IT 
mass analyzer to summarize their operation and application.  Arguably the most 
powerful feature of the IT is the ability to conduct multiple isolations and 
fragmentations (MSn), whereas, the QQQ is limited to a single fragmentation 
(MS2).  Further, the ability of the quadrapole of an IT to allow the accumulation of 
a specific ion, affords this mass analyzer some advantages in sensitivity.  It 
should be mentioned that the IT is able to operate under extremely high scan 
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speeds which allow it to detect a wider mass range of ions, however, when 
operating under such modes, there is a great loss in resolution.    
Whereas, the IT has many advantages for providing structural information, 
the IT lacks the dynamic or linear range present with QQQ analyzers.  While the 
trap can hold a large volume of ions, as the number of ions increases, space to 
charge dynamics hinder the performance of the analyzer.  The excellent dynamic 
range afforded by the QQQ, makes it the premier choice for the development of 
quantitative bioanalytical methods.    
 
1.5.4  Detectors 
 
The final component of a mass spectrometer is the detector(s).  The 
detector records either the charge or the current produced when an ion comes 
into contact with its surface.   There are many types of detectors available, table 
V. [20] summarizes the advantages and disadvantages of each type.  For this 
discussion, the electron multiplier and photomultiplier will be discussed.   
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 Table V., Characteristics of MS detectors   
 
 
 
 
  
•L
im
ite
d
 c
o
m
p
a
tib
ility w
ith
 m
o
s
t e
x
is
tin
g
 
in
s
tru
m
e
n
ts
 
•D
e
te
c
ts
 io
n
s
 in
d
e
p
e
n
d
e
n
t o
f m
a
s
s
 a
n
d
 ve
lo
c
ity 
C
h
a
rg
e
 D
e
te
c
tio
n
•R
e
d
u
c
e
s
 re
so
lu
tio
n
 
•E
x
p
e
n
s
ive
 
•F
a
s
t a
n
d
 s
e
n
s
itive
 
A
rra
y
•M
a
y s
h
o
rte
n
 life
tim
e
 o
f e
le
ctro
n
 m
u
ltip
lie
r 
•In
c
re
a
s
e
s
 h
ig
h
 m
a
ss
 s
e
n
s
itivity 
H
ig
h
 E
n
e
rg
y D
yn
o
d
e
s
 w
ith
 e
le
c
tro
n
 m
u
ltip
lie
r
•S
h
o
rte
r life
tim
e
 th
a
n
 s
c
in
tilla
tio
n
 c
o
u
n
tin
g
 
(~
3
 ye
a
rs
) 
•R
o
b
u
s
t 
•F
a
s
t re
s
p
o
n
s
e
 
•S
e
n
s
itive
 (≈
g
a
in
s
 o
f 1
0
6) 
E
le
c
tro
n
 M
u
ltip
lie
r
•C
a
n
n
o
t b
e
 e
xp
o
s
e
d
 to
 lig
h
t w
h
ile
 in
 
o
p
e
ra
tio
n
 
•R
o
b
u
s
t 
•L
o
n
g
 life
tim
e
 (>
5
 ye
a
rs
) 
•S
e
n
s
itive
 (≈
g
a
in
s
 o
f 1
0
6) 
P
h
o
to
m
u
ltip
lie
r C
o
n
ve
rs
io
n
 D
yn
o
d
e
 
(S
c
in
tilla
tio
n
 C
o
u
n
tin
g
)
•L
o
w
 a
m
p
lific
a
tio
n
 (≈
1
0
) 
•G
o
o
d
 fo
r c
h
e
ck
in
g
 io
n
 tra
n
sm
is
s
io
n
 a
n
d
 lo
w
 s
e
n
s
itivity 
m
e
a
s
u
re
m
e
n
ts
 
F
a
ra
d
a
y C
u
p
D
is
a
d
v
a
n
ta
g
e
s
A
d
v
a
n
ta
g
e
s
D
e
te
c
to
r
•L
im
ite
d
 c
o
m
p
a
tib
ility w
ith
 m
o
s
t e
x
is
tin
g
 
in
s
tru
m
e
n
ts
 
•D
e
te
c
ts
 io
n
s
 in
d
e
p
e
n
d
e
n
t o
f m
a
s
s
 a
n
d
 ve
lo
c
ity 
C
h
a
rg
e
 D
e
te
c
tio
n
•R
e
d
u
c
e
s
 re
so
lu
tio
n
 
•E
x
p
e
n
s
ive
 
•F
a
s
t a
n
d
 s
e
n
s
itive
 
A
rra
y
•M
a
y s
h
o
rte
n
 life
tim
e
 o
f e
le
ctro
n
 m
u
ltip
lie
r 
•In
c
re
a
s
e
s
 h
ig
h
 m
a
ss
 s
e
n
s
itivity 
H
ig
h
 E
n
e
rg
y D
yn
o
d
e
s
 w
ith
 e
le
c
tro
n
 m
u
ltip
lie
r
•S
h
o
rte
r life
tim
e
 th
a
n
 s
c
in
tilla
tio
n
 c
o
u
n
tin
g
 
(~
3
 ye
a
rs
) 
•R
o
b
u
s
t 
•F
a
s
t re
s
p
o
n
s
e
 
•S
e
n
s
itive
 (≈
g
a
in
s
 o
f 1
0
6) 
E
le
c
tro
n
 M
u
ltip
lie
r
•C
a
n
n
o
t b
e
 e
xp
o
s
e
d
 to
 lig
h
t w
h
ile
 in
 
o
p
e
ra
tio
n
 
•R
o
b
u
s
t 
•L
o
n
g
 life
tim
e
 (>
5
 ye
a
rs
) 
•S
e
n
s
itive
 (≈
g
a
in
s
 o
f 1
0
6) 
P
h
o
to
m
u
ltip
lie
r C
o
n
ve
rs
io
n
 D
yn
o
d
e
 
(S
c
in
tilla
tio
n
 C
o
u
n
tin
g
)
•L
o
w
 a
m
p
lific
a
tio
n
 (≈
1
0
) 
•G
o
o
d
 fo
r c
h
e
ck
in
g
 io
n
 tra
n
sm
is
s
io
n
 a
n
d
 lo
w
 s
e
n
s
itivity 
m
e
a
s
u
re
m
e
n
ts
 
F
a
ra
d
a
y C
u
p
D
is
a
d
v
a
n
ta
g
e
s
A
d
v
a
n
ta
g
e
s
D
e
te
c
to
r
  60 
Electron multipliers are comprised of a series of AlO3 dynodes held at increasing 
potentials.  When an ion strikes the surface, an electron is released.  The release 
of the first electron causes a chain reaction whereby a great number of electrons 
are released at each dynode.  This is sometimes referred to as an avalanche 
effect.  The large volumes of electrodes are collected by an anode, and thus a 
signal is recorded.  A simple diagram depiction of an electron multipliers is 
contained in figure 19.   
 Photomultipliers are similar in design to electron multipliers in that 
electrons bombard a phosphorous screen, as opposed to a dynode.  Photos are 
released from the phosphorous screen.  The photons then encounter a 
photocathode screen which results in the release of electrons.  The electrons 
then travel through the photomultiplier tube which operates as an electron 
multiplier, generating a cascade of electrons as discussed previously.  There is 
one main advantage of a photomultiplier over electron multiplier as the 
photomultiplier tube is sealed in a vacuum.  The vacuum prevents the detector 
from sources of contamination thus increasing the detector lifetime.   
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Figure 1.19, Electron multiplier process 
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Figure 1.20, Photomultiplier   
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1.6  Conclusion 
  
 This chapter has provided an overview of why it is necessary to develop 
quantitative bioanalytical methods, the determination of pharmacokinetics and 
pharmacodynamics.  Further, theory has been introduced regarding the all 
components of methods development.  A discussion of the extraction of 
pharmaceutical analytes from biological matrices has been presented, 
highlighting the common procedures used and the theory that dictates their 
success.  Thereafter, a detailed explanation of the instrumental setup and design 
of HPLC was presented.  A subsequent discussion of UV detectors followed, 
highlighting the usefulness of the detection methods.  Finally, the instrumentation 
and theory of mass spectrometers was presented.  Overall, this chapter should 
exhibit the profound understanding of many sophisticated components required 
to successfully develop a quantitative analytical method for the determination of 
pharmaceutical compounds.   
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CHAPTER II 
 
 
THE DEVELOPMENT OF QUANTITATIVE BIOANALYTICAL 
METHODS FOR THE DETERMINATION OF CANNABINOID ANTAGONISTS 
RIMONABANT AND SURINABANT 
 
 
 
 
2.1  Introduction to Cannabinoids 
 
2.1.1  Cannabinoid Discovery 
 
Cannabinoids are a class of compounds which are found in the cannabis  
plant.  Cannabinoids also refer to a broad class of compounds which include:  
those structurally related to tetrahydocannabinol (THC); compounds which bind
  68 
to the cannabinoid (CB) receptors; and eicosanoids, which are related to 
endocannabinoids.    
The discovery of cannabinoids began with the isolation of THC, the primary 
psychoactive component of the cannabis plant in 1964 [1].  THC is a compound 
which can induce feelings of euphoria, stimulate appetite, and reduce pain [2].   
In the body THC is metabolized to 11-hydroxy-THC which continues to 
possess psychoactive properties.  The metabolite is further oxidized to 11-Nor-9-
carboxy-THC.  Over 100 metabolites of THC have been identified in humans and 
animals, but 11-hydroxy-THC and 11-Nor-9-carboxy-THC are the most prevalent.   
THC is metabolized in the liver via p450 enzymes and predominantly excreted in 
feces (55%) with 20% being excreted in urine [3].   
The interesting psychoactive properties of THC have led to it use as a 
therapeutic agent in the treatment of both cancer and AIDS due to its analgesic, 
appetite stimulating properties.  Its success in these treatments has opened the 
door to widespread research aiming to elucidate the mechanisms of action of this 
exciting class of compounds.   
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Figure 2.1,  Chemical structure of THC 
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2.1.2  Endogenous Cannabinoid System (ECS) 
  
The discovery of THC and the physiological processes it affects has led to the 
study of a complex signaling system, termed the endocannabinoid system (ECS).  
The endocannabinoid system consists of:  cannabinoids, both endogenous and 
exogenous; proteins which are involved with the synthesis and inactivation of 
cannabinoids; cannabinoid (CB) receptors; and biochemical pathways which are 
affected by cannabinoids.   
Prior to discussing the ECS, it is necessary to explain normal and retrograde 
neurotransmission.  In normal neurotransmission, neurotransmitter are released 
from the presynaptic neuron, travel across the synaptic cleft, and bind to their 
receptor on the postsynaptic neuron.    
Cannabinoids, both endogenous and exogenous, participate in retrograde 
neurotransmission.    In retrograde neurotransmission (Figure 2.3), the 
neurotransmitter (cannabinoid) is released from the postsynaptic neuron and 
binds with a receptor on the presynaptic neuron [4].   
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Figure 2.2, Normal neurotransmission
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Figure 2.3, Retrograde neurotransmisson 
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The exogenous cannabinoid, THC has been discussed.  There are also 
endogenously produced cannabinoid or endocannabinoids (EC‟s).  Two EC‟s 
have been identified, anandamide (AEA) and 2-arachidonyl glycerol (2-AG).  
Both compounds are metabolites of arachidonic acid [5].    
When the ECS is functioning normally, the synthesis of EC‟s is initiated by 
membrane depolarization on the postsynaptic neuron which causes an influx of 
Ca2+ into the neuron.  Ca2+ activates the enzyme transacylase which catalyzes 
the first step of synthesis by converting the membrane phospholipid 
phosphatidylethanolamine to N-phosphatidylethanolamine (NAPE).  In one 
proposed mechanism, NAPE is further cleaved to yield the EC, AEA [6].   
The EC‟s are highly lipophillic, and are able to cross the cellular membrane of 
neurons freely, as opposed to being stored in vesicles, as required for most 
neurotransmitters.  The synthesis of the EC‟s happens rapidly, when required, 
and they are quickly degraded by fatty acid amide hydrolase (FAAH)   back to 
arachidonic acid plus ethanolamine (AEA) or glycerol (2-AG) [7].   The reaction 
scheme for the biosynthesis of EC‟s is presented in figure 2.5. 
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Figure 2.4, Chemical structure of AEA and 2-AG 
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Figure 2.5, Biosynthesis of AEA and 2-AG    
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Both exogenous cannabinoids and EC act on the CB receptors.  CB receptors 
are a class of G-protein coupled receptors.  G-protein coupled receptors are 
seven domain, transmembrane proteins.  Transmembrane proteins are affected 
by compounds outside of the cell and cause a biochemical response within the 
cell.   
There are two classes of CB receptors, CB1 and CB2.  CB1 receptors are 
primarily concentrated in the brain and nervous system.  CB2 receptors are 
located expressed in the immune system and Hematopoietic stem cells (HSCs).  
There is also evidence for CB receptors which do not belong to the CB1 or CB2 
subtypes [8], however, there is little understood about these receptors.   
It has been reported that the CB1 receptor is the most widely expressed  
receptor in the brain [9].  A diagram which depicts the areas of the brain where 
the CB1 receptor is expressed is contained in figure 2.7 [9].   When the CB1 
receptor is activated by cannabinoids, it is though to cause neuronal membrane  
depolarization which causes a reduction in GABA neurotransmission.  The CB1 
receptor is also expressed in other tissues, notably the liver, where its activation 
stimulates lipogenesis [10].    
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Figure 2.6, Protein structure of the CB1 receptor [8] 
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Figure 2.7, Areas of the brain with CB1 receptor expression 
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As previously mentioned, the CB2 receptor is expressed predominantly in 
immune cells, suggest a role in the function of the immune system.   Research 
on the CB2 receptor has shown that it may affect macrophage-mediated helper T 
cell activation [11].    Although some CB2 receptors have been isolated from 
brain tissue, the role of this receptor in the nervous system is not well studied.   
Cannabinoid binding to the CB receptor causes a wide range of biochemical 
responses.  The activation of CB1 receptors causes the inhibition of cyclic 
adenosine monophosphate (cAMP), a secondary messenger involved in 
transferring the signal of many extracellular molecules [12].  Further CB1 
activation causes an inhibition of voltage activated Ca2+ channels and activates 
inwardly rectifying K+ channels.  The inhibition of Ca2+ combined with the 
activation of K+ together inhibits the release of neurotransmitters [13].  Finally CB 
activation has to increase the activity of mitogen activated protein kinase (MAPK) 
which affects several gene transcription factors including c-Fos and Krox-24 [14].   
In addition to the biochemical processes which cannabinoids affect, there are 
several behavioral or physiological consequences to CB receptor activation.  
These processes include, but are not limited to:  feeding response; energy 
balance and metabolism; pain perception; and memory, learning and emotion [5].   
As evidenced in figure 2.7, CB1 receptors are highly expressed in the 
hypothalamus and dopamine reward regions of the brain.  These brain regions 
are known to affect food intake, energy balance and reward systems.  Therefore, 
cannabinoids and the modulation of the ECS is the subject of strong investigation 
for its potential role in the treatment of obesity and drug addiction.   
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2.1.3 Cannabinoid Antagonists 
As discussed in the previous section, cannabinoids, particularly EC‟s are 
fervently being investigated to understand how their modulation can be used to 
treat several conditions.  One facet of this investigation revolves around 
compounds which act to inhibit the biochemical and physiological response to 
EC‟s.   
The rationale of blocking the cannabinoids from binding to the CB receptor 
has shown to have two principle therapeutic outlooks; the treatment of obesity 
and metabolic disorders, and as a treatment for addiction to drugs of abuse.  
Studies show that by blocking EC‟s, there is a reduction in food intake.  Further, 
when the CB1 receptor is not activated, there is effect on metabolism, causing 
the body to use energy more efficiently.  Finally, lipogenesis, the generation of fat 
cells is slowed by the inhibition of CB receptors.   
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Figure 2.8, Overview of the affect of the ECS on food intake, energy storage 
and balance 
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The biological responses caused by the blocking the activation of CB 
receptors that implicate this process as a potential treatment for drug abuse are 
related to the neurotransmitter, dopamine and the dopamine dependant 
mesolimbic reward system [15].  As described previously, the binding of EC‟s has 
an effect on ion transport in the central nervous system which inhibits the normal 
release of neurotransmitters, including dopamine.   The release of dopamine 
causes a general sense of well being and is required for an animal to function 
normally.   By blocking the EC‟s from their site of action, the release of dopamine 
is restored.   
The second facet of the rationale for inhibiting CB receptors to treat drug 
addiction involves the mesolimbic reward system.  The release of dopamine 
affects the brains reward system by essentially reinforcing certain behaviors.  It is 
accepted that this reward system participates is the biological basis of drug 
addiction.  Though not well understood, it is suggested that blocking the EC‟s 
from binding permits a modulation of the brains reward system and thus, may 
have promise as a treatment for drug addiction.   
The compounds which inhibit the CB receptors are often referred to as 
cannabinoid or endocannabinoid antagonists, or inverse agonists [16].  For 
clarity, several terms should be defined:  agonist, a molecule which stimulates a 
cellular response by inducing a conformational change in the receptor; 
antagonist, a compound which is unable to cause the conformational change 
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required to stimulate a cellular response; and inverse agonist, which causes a 
stabilization of the receptors conformation and causes a response inverse to that 
of the agonist.   
It is possible to further describe the different type of receptor binding using a 
two state model.  In this model, receptors are either active or inactive.  Agonists 
bind to receptors that are in the active state and have a stimulatory effect.  
Antagonists can bind to a receptor in either the active or inactive state.  Inverse 
agonists only bind to the inactive state of a receptor, causing an inhibitory effect.    
There is evidence that the CB inhibitors discussed in the next sections act as 
both inverse agonists, as well as antagonists.  In vitro, at clinically relevant 
doses, these compounds act as antagonists; but at higher doses, behave as 
inverse agonists [16].  It is not currently known the type of inhibition that is 
caused in vivo.   For purposes of consistency and clarity, all references to 
compounds which inhibit CB receptors will be referred to as antagonists.   
 
2.1.4  Rimonabant 
 
Rimonabant [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)- 
4-methyl-1 H-pyrazole-3-carboxamidehydrochloride)], the first selective CB1 
receptor antagonist was discovered in 1994 [17].  The chemical structure of 
rimonabant is contained in figure 2.9.  Rimonabant has been shown to be orally 
active.  Further, administration of rimonabant is ably to fully antagonize the 
effects of the CB receptor agonist, THC.   
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Figure 2.9, Chemical structure of rimonabant 
 
 
O
NH
N
N
NH
H3C
Cl
Cl
Cl
  85 
Rimonabant has been investigated as a therapeutic agent for the  
treatment of both obesity and drug addiction.  The administration of rimonabant 
to rodents has shown to reduce the rewarding/reinforcing behaviors of several 
drugs of abuse including heroin [18], cocaine [19], nicotine [20] and alcohol [21].   
Further, there is evidence that rodents administered this drug show a marked 
decrease in food consumption [22] .  
Rimonabant has been investigated in a phase II clinical trial to be used in the 
treatment of alcoholism [23], a phase III clinical trial for treatment of diabetes [24] 
and a phase III clinical trial for treatment of obesity [25].    In 2006, rimonabant 
was approved under the brand name Acomplia by the European Union as an 
over-the-counter medication.  In October of 2008, the European Medicines 
Agency (EMEA) recommended that the use of Acomplia be suspended [26].   In 
November of 2008, the manufacturer of Acomplia, Sanofi Aventis, discontinued 
production of the drug.  The reasons that Acomplia has been abandoned as a 
therapy relate to unwanted neurological side effects, particularly depression.  It 
has been stated that patients taking Acomplia have twice the risk of developing 
depression than those taking placebo [27].   
Despite rimonabant being removed from the drug pipeline, there continues to 
be a strong interest in its molecular modes of action and the behavioral 
responses which are generated.  In fact, in the first half of 2009 over 50 
publications have been generated further investigating this drug.  Further, many 
publications are the result of animal behavior studies.   
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One of the aims of this work is to present the development of a quantitative 
bioanalytical method, using HPLC-MS/MS,  for the determination of rimonabant 
in biological samples.  Prior to the development of the method discussed in the 
next sections, no method was publicly available.  This method is able to measure 
rimonabant in human, rat and canine plasma; as well as, in rat brain tissue.  The 
method developed has been applied to the measurement of rimonabant in two 
separate animal studies.   Further, the method can be applied to future clinical 
and toxicological studies to establish pharmacokinetic and phamacodynamic 
profiles in various animal models.  This work will remains a valuable resource to 
the research community as a better understanding of the ECS and the 
compounds which modulate it, emerges.   
 
 
2.1.5  Surinabant 
 
Surinabant [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-
piperidinyl)-1H-pyrazole-3-carboxamide] is an CB receptor antagonist, which was 
developed by Sanofi Aventis [28].  The chemical structure of surinabant is 
contained in figure 2.10.   
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Figure 2.10, Chemical structure of surinabant 
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Surinabant is a second-generation CB receptor antagonist.  It has a longer 
duration of action than the rimonabant, and enhanced oral activity [29] [30] [31]. 
Further, surinabant may have advantages over rimonabant in that it is reported 
that surinabant has both a higher affinity for CB receptors in the brain and has up 
to three times longer occupancy in the brain [32]. 
Surinabant differs structurally from rimonabant in that it has an ethyl group 
attached to the central nitrogen ring versus a methyl group in this position on 
rimonabant.  It has been suggested that the enhanced biological effects of 
surinabant are due to its slightly larger hydrophobicity.  Greater hydrophobicity 
has two main effects, it is able to cross the blood brain barrier more rapidly; and it 
may move more easily across the through the membrane of post synaptic 
neuronal cells.   
Surinabant has been in clinical trials in Europe for treatment of both obesity 
[33] and nicotine addition [34].  Current research using surinabant elucidates a 
relationship between nicotine, metabolism and weight gain [35].  It has further 
been investigated for the treatment of alcoholism and attention deficit 
hyperactivity disorder (ADHD).  Evidence for the potential of surinabant in the 
treatment of alcoholism is shown in a study that describes the administration of 
surinabant is able to reduce both voluntary ethanol consumption as well as 
alcohol intake [13]. 
Clinical trials have been completed, and this compound has been removed 
from the drug pipeline of Sanofi Aventis.  Despite the noticeable abandonment of 
this compound, there is a great deal that remains unknown about the ECS.  The 
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method developed for the determination of rimonabant was quickly responded to 
with enthusiasm by the research community.  It is logical that a method that can 
measure a compound which varies only slightly in chemical structure, yet has 
markedly increased biological responses; would be a valuable tool for the 
scientific community.   
The work described here will outline the development both an HPLC-UV and 
an HPLC-MS/MS quantitative bioanalytical method, for the determination of 
surinabant in biological matrices.  Prior to the publication of this work, no method 
was publicly available to measure the concentration of surinabant in any 
biological matrix.  
 
2.1.6  Conclusion   
 
The endocannabinoid system (ECS) is a complex signaling system that  
affects several biological events including; regulating energy balance and 
behaviors such as food intake, fear and anxiety.  As previously discussed, ECs 
are biochemically involved in many physiological processes, including food intake 
and addiction.  Naturally, compounds which are able to modulate, via agonism or 
antagonism, the ECS are of great interest.   
 The work presented in this chapter will describe quantitative, bioanalytical 
methods that can be used to measure the concentration of the CB receptor 
antagonists, rimonabant and surinabant.  These methods have been applied to 
animal studies.  To date, the data obtained from the use of these methods has 
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aided researchers in the fields of psychiatry and metabolic disorders to further 
understand and interpret their experimental results.  The future applications of 
these methods cannot be predicted; however, the value to science is clearly of 
great value.   
 
2.2   Development of a Quantitative Bioanalytical Method for the 
Determination of Rimonabant 
 
2.2.1  Introduction   
 
Prior to the development of the method presented in this section, there 
was no publicly available method to measure the concentration of rimonabant 
in biological samples.  A HPLC-MS/MS method was developed and validated 
using a human plasma matrix.  In addition to human plasma, successful 
measurement of rimonabant was achieved in the following matrices:  rat 
plasma, rat brain and canine plasma.  For this work validation was conducted 
to demonstrate the robustness and reproducibility of the method.  All 
validation parameters followed the guidelines contained in the document, U.S. 
Food and Drug Administration Bioanalytical Method Development – Guidance 
for Industry [36] 
 
 
 
  91 
2.2.2  Materials and Methods 
 
Reagents 
 
Acetic acid, HPLC-grade acetonitrile, dimethyl sulfoxide (DMSO), formic acid, 
and 1- (2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-
pyrazole-3-carboxamidetrifluoroacetate salt (AM251, the internal standard for this 
study), Cremophor EL, and Tween 80 were purchase from Sigma-Aldrich (St. 
Louis, MO, USA).  Rimonabant, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-
methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide was provided, at no cost, by 
National Institute of Mental Health (Bethesda, MD, USA) Drug Repository (NIMH 
code 5S-705.)  Dr. Michael Kalafatis at Cleveland State University, graciously 
donated pooled human plasma was from Haemtech, Inc (Essex Junction, 
Vermont, USA).  
The rimonabant (C22H21Cl3N4O) stock solution (1.00 mg/ml) was prepared by 
weighing1.12 mg of the compound into a 1.5 ml Eppendorf tube (Eppendorf, 
Westbury, NY, USA) and dissolving it with 1.12ml of DMSO. A stock solution 
(1.00 mg/ml) of AM251 trifluoroacetate salt (C22H21N4OCl2I · C2HF3O2) was 
prepared by weighing 1.24 mg of the compound into a 1.5 mL Eppendorf tube 
and dissolving it with 1.24 ml of DMSO.  
Once the compounds were dissolved in DMSO, both rimonabant and AM251 
stock solutions were transferred to 1.5 ml amber glass autosampler vials, sealed 
with parafilm, and were stored at - 20 ºC when not in use.  A rimonabant working 
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solution (100 μg/ml) was prepared by a dilution (1/10) of the rimonabant stock 
solution with DMSO. A working solution (2.00 μg/ml) of AM251 was prepared by 
a three-step dilution (1/8.3, 1/10, 1/5) of the AM251 trifluoroacetate salt stock 
solution with DMSO. A mobile phase for liquid chromatographic separation was 
prepared by first adding formic acid (HCOOH) to water.  The formic acid/H2O 
solution was mixed with acetonitrile (50:50 v/v) with the HCOOH concentration 
being 0.1% of the final mobile phase volume.  All solutions were stored at 4◦C 
when not in use. 
 
Calibrators and Controls 
 
Pooled human, Sprague-Dawley rat and mixed breed canine plasmas which 
contained no detectable rimonabant were used as the blank plasmas to prepare 
human and rat plasma calibrators and controls for this study. Standard solutions 
of rimonabant (0.0100, 0.0200, 0.100, 0.150, 0.200, 1.00, 1.50, 2.00, 10.0,15.0, 
20.0 μg/ml) were prepared by a serial dilution of the working solution (100 μg/ml) 
with DMSO. Plasma calibrators of rimonabant (0.500, 1.00, 5.00, 10.0, 50.0, 100, 
500, 1.00 x 103 ng/ml) were prepared by a 1:20 dilution of the corresponding 
rimonabant standard solutions with the blank plasma.  A 1:20 dilution of the 
corresponding rimonabant standard solutions with the blank plasma was 
conducted to prepare the rimonabant plasma controls (7.50, 75.0, 750 ng/ml). All 
plasma samples were stored at – 20◦C when not in use. 
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Protein Precipitation 
 
Rimonabant was extracted from plasma samples using the following protocol:   
First, 200 μl of plasma sample was pipetted into a 1.5 ml Eppendorf tube; 
thereafter, 10.0 μl of the AM251 working solution (2.00 μg/ml) and 50.0 μl of 
acetic acid were added to the mixture. The mixture was vortex mixed and 1.00 ml 
of acetonitrile was added. The ACN/plasma solution was then vortexed again 
subsequently centrifuged for 15 minutes at 13,000 g.   The supernatant present 
after centrifugation was transferred to a 1.5 ml Eppendorf tube, and evaporated 
to dryness in a DNA 120 SpeedVac® (ThermoSavant, Hollbrook, NY, USA) at 65 
ºC for 90 min. The sample was reconstituted in 200 μl of the mobile phase prior 
to analysis. 
 
Rimonabant Recovery 
 
The ability of the protein precipitation procedure to recover rimonabant by 
was measured using rimonabant plasma controls and rimonabant reference 
solutions at three different concentrations (7.50, 75.0, 750 ng/ml). The reference 
solutions contained the same matrix as that of plasma controls, which were 
prepared using blank plasma as samples by the same extraction procedure as 
that of plasma controls, and reconstituted in the mobile phase with corresponding 
rimonabant concentrations. 
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 Animal Samples (rat) 
 
Sprague-Dawley rats (Taconic Farms) were bred in the vivarium of 
Binghamton University.  On postnatal (P) day 1, litters were chosen   with 7-10 
subjects, whenever possible retaining six males and four females. Animals were 
weaned on P21, housed in same-sex pairs and maintained on a 14/10 hour 
light/dark cycle (lights on at 7 am) with food and water available ad libitum. All 
experimental procedures were approved by the Institutional Animal Care and 
Use Committee at Binghamton University.  The animals were an average 70 
days old. The average body weight of the animals was 300 grams. Rimonabant 
was delivered as a suspension of 2.0% Cremaphor EL, 0.1% Tween 80 and 
deionized water. Intraperitonal (i.p.) injections of 10 mg/kg in a volume of 5 ml 
were administered. The animals were decapitated at 30 minutes and 12 hours. 
Trunk blood samples were obtained by allowing the blood to freely drain into 
centrifuge tubes. An average of 3 mL of blood was collected from each animal in 
tubes containing 0.1 ml of 0.1 M EDTA. High-speed centrifugation was used to 
separate the plasma from whole blood. Plasma was stored at - 80 ºC until 
analysis. 
 
Animal Samples (canine) 
 
Mixed breed canine plasma collected using lithium/heparin (Li-Hep) as an 
anticoagulant was purchased from Lampire Biological Laboratories (Pipersville, 
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PA, USA).   Dr. Joyce Richey at the University of Southern California, Keck 
School of Medicine provided the canine samples to be analyzed.  The plasma 
was collected in Li-Hep coated test tubes and EDTA was added to the plasma.  
No further information regarding the breeding or dosing of animals, nor the 
collection or storage of plasma was provided.   
 
Instrumental Setup 
 
The instrumental setup used in this work consisted of an HP1100 pump by 
Hewlett Packard (Palo Alto, CA, USA), an HP1100 autosampler, a stainless steel 
in-line filter (0.5 μm pore, 0.23 μl dead volume) by Upchurch Scientific (Oak 
Harbor, WA, USA), a YMCTM Pro C4  cartridge column (3 μm, 120 Å, 2.0 mm x 
50 mm) by Waters (Milford, MA, USA), a stainless steel splitting tee (1/16” x 0.25 
mm) by Valco (Houston, TX, USA), and a Quattro II triple quadrupole mass 
spectrometer by Micromass (Manchester, UK). All fluidic connections in the 
system were made using high-pressure polyether ether ketone (PEEK) tubing 
(0.0625 in. o.d., 0.0100 in. i.d.). The post-column split ratio was 1:2 with a smaller 
flow (ca. 63 μl/min) to the MS detector and the larger one to the waste. 
 
HPLC Separation 
 
Analytical separation was performed via a Waters YMCTM Pro C4 cartridge 
column. Before analysis, the cartridge column was equilibrated with  mobile 
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phase at a flow rate of 0.200 ml/min for about 15 min. During the analyses, 20 μl 
of sample was injected by the autosampler and carried onto the cartridge column 
by the mobile phase at a flow rate of 0.200 ml/min. Rimonabant and AM251 
(internal standard) were separated from the sample matrix with retention times of 
6.8 and 7.8 min, respectively. The total run time was 10.0 min per sample. 
 
  MS Detector Settings 
 
Electrospray ionization mode (ESI+) was utilized on the Micromass Quattro II 
triple quadrupole mass spectrometer. Tuning of the mass spectrometer was 
achieved by infusion of a mixture of rimonabant (1.0 μg/ml) and AM251 (1.0 
μg/ml) in the mobile phase at a flow rate of 3.0 μl/min with a syringe pump 
(Harvard Apparatus, South Natick, MA, USA). Optimal ionization conditions were 
as follows: nitrogen sheath and desolvation gas at 10 and 350 l/h, capillary at 3.5 
kV, HV lens at 0.5 kV, cone at 40 V, skimmer at 1.5 V, RF lens at 0.2 V, ion 
source temperature at 95◦C, ion energy at 1.0 V, low- and high-mass resolution 
at 15, and multiplier at 700 V. Full-scan spectra were acquired in the continuum 
mode at a scan rate 400 u/s.  The instrument was operated in multiple reaction 
monitoring (MRM) mode for quantitation, which was set as follows: m/z 463 → 
363 for rimonabant, m/z 555 → 455 for AM251, argon collision gas at 2.0-2.5 
μbar, cone at 40 V, collision energy at 20 V for both analytes, low- and high-mass 
resolution at 10 for quadrupole 1 and 15 for quadrupole 3, dwell time at 0.1 s, 
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and the inter-scan delay at 0.01 s. The parameters for ionization remained the 
same as previously discussed.   
 
Analysis of Data 
 
Data acquisition and peak integration were performed using the Micromass 
Masslynx software (version 3.4). The peak area ratios of rimonabant plasma 
calibrators to the internal standard were plotted against plasma rimonabant 
concentrations for a regression equation. Rimonabant concentration of an 
unknown plasma sample was determined by the regression equation after 
obtaining the peak area ratio of rimonabant in the unknown to the internal 
standard from the mass chromatogram.   
 
2.2.3  Results and Discussion 
 
Selection of Solvent for Stocks, Plasma Calibrators and Controls  
 
Rimonabant and AM251 are caboxamide derivatives which are not  
water soluble.  In many situations, the addition of acid to a solution will protonate 
the compound and, due to ionization, improve its water solubility.  In this work 
0.1M hydrochloric acid (HCl) was added to the solution which was not able to 
sufficiently aid in the solubility.   
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Due to the hydrophobicity of these compounds, it was not possible to dissolve 
them directly into plasma and a suitable stock solution solvent was required.  
Both compounds were easily dissolved in both acetonitrile (ACN) and methanol 
(MeOH).  However, it has been established that when these solvents are used to 
prepare stock solutions, the subsequent addition to plasma can cause protein 
precipitation, in amounts less than 1% [37].  Protein precipitation may result in 
poor precision of the analytical method.   
DMSO was investigated as a potential alternative to ACN and MeOH.  Both 
rimonabant and AM251 were readily soluble in DMSO, and up to a 25% addition 
of DMSO to plasma did not result in appreciable protein precipitation.  Therefore, 
DMSO was selected as the solvent for all stock and working solutions.   In order 
to assure that no precipitation would occur, DMSO was limited to 10% v/v in all 
plasma controls and calibrators.  
 
Extraction of Analyte and Recovery 
 
As described in section 1.2, the first step in bioanalytical method  
development is the extraction of the analyte from the biological matrix which it 
exists in.  In the case of rimonabant, on-line sample extraction was first 
considered.  On-line sample extraction is solid phase extraction (SPE) conducted 
“on-line”, or in the automated set-up of the instrumental procedure.  SPE is 
discussed in detail in section 1.2.4.    
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The automated nature of on-line SPE provides several advantages over SPE:  
cost, the column used for extraction is reused, up to hundreds of times; precision, 
there is no pipetting involved in sample loading which reduces human error; and 
time, the automation of the process allows for much faster extractions than that 
of SPE.   Unfortunately, the hydrophobic nature of rimonabant caused a 
significant carryover of sample between injections, and thus on-line extraction 
was abandoned.   
Since on-line extraction was not possible, a protein precipitation protocol was 
developed.  The protein precipitation utilized 100% ACN, as the extraction 
solvent.  Prior to the addition of ACN, acetic acid was added to the plasma.  The 
addition of acid protonates the plasma proteins, which can serve to reduce the 
binding of drug with plasma proteins.  Further, protonation disrupts the hydration 
layer of proteins in solution as discussed in section 1.2.3.  This disruption can 
reduce the aggregation of proteins which can lead to poor reproducibility and 
recovery. 
The recovery of rimonabant was ascertained at three concentrations, low (7.5 
ng/mL), middle (75.0 ng/mL) and high (750 ng/mL).  Recovery describes the 
difference between the mean peak area ratio of the signal of rimonabant 
obtained from samples which were spiked with rimonabant prior to the protein 
precipitation, to the signals obtained from samples spiked with rimonabant after 
the protein precipitation.  Both absolute recovery, the recovery of rimonabant 
alone; and relative recovery, the internal standard corrected recovery was 
calculated. 
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Figure 2.11, Benefit to using DMSO and acetic acid in protein precipitation 
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  101 
According the FDA‟s guidance for the industry, there is no absolute value for 
recovery required.  It is only necessary that the recovery be consistent and 
reproducible across the concentration range of interest.  The absolute and 
relative recoveries of rimonabant from the human plasma matrix are contained in 
Table V. 
 The recovery of rimonabant in canine plasma was verified at the low, 
medium and high concentrations described above and were determined to be:  
89.8%, 89.4% and 91.7 %, respectively.  As clearly indicated by table V 
combined with the values obtained using canine plasma, the protein precipitation 
protocol is suitable for the extraction of rimonabant from these matrices.   
It is worth mentioning that the use of 70% ACN as the extraction solvent was 
investigated.  The rationale for using a lower amount of ACN was an attempt to 
reduce cost due to solvent consumption.  The reduced ACN resulted in lower 
extraction efficiency.  The poor recovery can be attributed to a change in the 
partitioning of the compounds when a lower amount of ACN was used, as 
discussed in section 1.2.2.  
  102 
 
 
Table VI, Recovery of rimonabant in human plasma 
 
 
  
The number of measurements was 3 for each datum point.
The concentration of the internal standard AM251 was 100 ng/ml.
199.20.692.0395.2SR141716/AM251
485.8491.0387.3AM251
585.1483.7283.0SR141716
CV (%)Recovery (%)CV (%)Recovery (%)CV (%)Recovery (%)
750 ng/ml75.0 ng/ml7.50 ng/mlCompound
Absolute and relative recoveries of rimonabant and AM251 in human plasma
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HPLC Separation 
  
 Although neither the MS detector, nor the application of the method, 
required that rimonabant and AM251 be chromatographically separated; this 
achievement would result in better method sensitivity.  Therefore, several 
analytical columns and mobile phase compositions were tested to first, achieve 
baseline separation and secondly, assure that the retention times were not 
inhibitorily long.   
The first conditions tested used a Waters YMC™Pro C18 column (3 μm, 120 
A°, 2.0mm×50 mm) and a mobile phase containing 90% CH3OH/0.1% HCOOH in 
water, rimonabant and the AM251 were co-eluted at retention times of 2.5 and 
2.8 min.  Next a mobile phase of 70% CH3CN/0.1% HCOOH in water, it was 
possible to achieve baseline separation of rimonabant and the internal standard 
with retention times of 4.6 and 5.6 min on the Waters YMC™ Pro C18 cartridge.   
As discussed in section 1.1, a good bioanalytical method will aim to keep  
the cost as low as reasonable.  Therefore, in an effort to reduce the amount of 
ACN in the mobile phase, a Waters YMC™ Pro C8 cartridge column (3 μm, 120 
Å, 2.0 mm x 50 mm) was tested. With the mobile phase composition of 50% 
CH3CN/0.1% HCOOH in water, rimonabant and AM251 were partially separated 
at 13.5 and 17.0 min.   
Again, it is desirable to maintain a short analysis time so, to reduce the 
separation time, a Waters YMC™ Pro C4 cartridge column (3 μm, 120 Å, 2.0 mm 
x 50 mm) and a mobile phase composition of 50% CH3CN/0.1% HCOOH in 
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water were used.   This column and mobile phase system allowed for separation 
of rimonabant and AM251 with retention times of 6.8 and 7.8 min.  Therefore, a 
Waters YMC™ Pro C4 cartridge column and a mobile phase composition of 50% 
CH3CN/0.1% HCOOH in water were utilized for the subsequent analytical 
separations.  Representative mass chromatograms of rimonabant and AM251 
using this chromatographic systems are contained in figure 2.12. 
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Figure 2.12, Representative mass chromatograms of rimonabant and AM251 
in (A) untreated blank plasma, (B) plasma treated with rimonabant only, and 
(C) plasma treated with 100 μL of both rimonabant and AM251 
AM251 
rimonabant 
rimonabant 
rimonabant 
AM251 
AM251 
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MS Detection 
 
Section 1.5 describes the theory of mass spectrometry detectors, indicating 
that the mass to charge or m/z ratio of ions is detected.  Most modern instrument 
are capable of analyzing:  positive ions, i.e. the molecular weight of the analyte 
plus a proton or M+H+; negative ions,   i.e. the molecular weight of the analyte 
minus a proton or M -H+; or alternating between positive and negative ion 
detection.   
This work used the MS instrument in multiple reaction monitoring mode 
(MRM).  This is a feature of most sophisticated instruments in use today.  In 
MRM mode, the detector is able to operate and record data for multiple analytes 
simultaneously.  Therefore, the signal for the analyte and internal standard can 
be extracted from the total ion signal during the data processing step.   
Based on the chemical structures of rimonabant and AM251, they will more 
easily undergo protonation than deprotonation, therefore positive electrospray 
ionization mode was employed for their detection.   The full-scan spectra showed 
that rimonabant produced a predominant quasi-molecular ion at m/z 463 and 
AM251 at an m/z of 555. Therefore, these ions were chosen as parent ions for 
fragmentation in the MRM mode.    
The daughter spectra of the parent ions revealed that the predominant 
daughter fragments were at m/z 363 for rimonabant and m/z 455 for AM251.  
These daughter ions were chosen for analyte quantitation.  The full scan and 
daughter fragmentation spectra are contained in figure 2.13.   
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Figure 2.13, Full scan spectra of (A) rimonabant, (B) AM251; daughter 
spectra of (C) rimonabant and (D) AM251 
(A)  rimonabant 
(B)  AM251 
(C)  rimonabant 
daughter ions 
(C)  AM251 
daughter ions 
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The use of MRM mode for detection of rimonabant and AM251 offered 
suitable specificity, which is exhibited by the lack of interference from any 
compounds in the blank plasma, as demonstrated in figure 2.12.   
The fragmentation scheme for rimonabant and AM251 can be proposed 
based upon the fact that the predominant daughter ions were 100 amu less than 
their parent ions.   
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Figure 2.14, Proposed fragmentation scheme for rimonabant (SR141716) and 
AM251 
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Method Validation (Linearity, Detection Limits, Precision, Accuracy and 
Stability) 
 
Via Human Plasma for Rat Study 
  
 As described in section 2.2.2 the volume of rat plasma obtained from each 
animal was limited to 3.0 mL.  Several validation parameters were tested to 
assure that the difference in matrix had no appreciable affect on the validation.  
Therefore, due to the limited supply of blank rat plasma this method was 
validated using blank human plasma.   
 The linearity of the response of the detector was determined by the peak 
area ratios of rimonabant to the internal standard and plotted versus the 
concentration of plasma calibrators.  This method has a linear range of 5.00 – 
1000 ng/mL with a correlation coefficient of 0.999.  The mean calibration 
equation, determined from three separate calibration curves over a 6 month 
period was y = 0.0196x.   
The guidelines prescribed by the FDA industry guidelines sets forth several 
values for acceptable detection limits, precision, accuracy and stability.  These 
values require that the limit of detection (LOD) and limit of quantitation (LOQ) 
must be 3 and 10 times the signal to noise, respectively.  The calculated LOD 
and LOQ for this method (based on 5 replicates) are 1.09 and 3.62 ng/mL, 
respectively.    
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The precise detection of all samples should be accomplished with less than 
15% (20% at the lowest concentration) error to ensure the reproducibility of the 
entire method.  The intra-assay precision, or the precision afforded by the mass 
spectrometer was determined for this method.  Additionally, the inter-assay 
precision from sample to sample, an indication of the human precision of the 
method was also determined.  All precision values are reported as %CV which is 
calculated by dividing the standard deviation by the mean value and multiplying 
by 100.    The precision values calculated are contained in table VI.   All values 
reported are internal standard corrected.   
The accuracy, which is determined by the relationship of the measured 
concentration of analyte to the real concentration, should also be within 15%.   
The equation used to calculate accuracy is contained in equation 2.1.   
 
[[(real concentration – measured concentration) / real concentration] x 100] 
 
The accuracy of this method was ascertained at 7.5, 75.0 and 750 ng/mL and 
was found to be 105, 99.5 and 100% respectively.  These values fall within the 
15-20% error window suggested in the FDA guidelines.  
(2.1) 
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Table VII, Intra-and inter-assay precision of rimonabant measurement 
 
 
 
 
The concentration of the internal standard AM251 was 100 ng/ml.
The number of measurements was 3 for each datum point.
20.4750
0.5175.0
60.97.50
Inter-runIntra-run[SR141716] (ng/ml)
CV (%)
Intra- and inter-assay precision of rimonabant in human plasma
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 Finally, it is important to determine the stability of the analyte under 
conditions anticipated to be appropriate for the methods application.  In this 
method, the freeze/thaw (3 cycles; -20◦ → room temperature), and short term 
mobile phase (stock) and plasma (calibrator) stability was ascertained.  Error was 
measured as the difference in signal obtained from the analyte after subjecting 
the samples to the condition to the signal of the analyte at time zero.  The 
stability was investigated at both low and high concentrations.    Under the 
conditions studied, the error ranged from 6.6 to 8.9%, which indicates that 
rimonabant is stable under these circumstances. 
 
Canine Plasma 
 
Before being applied to the canine plasma samples the accuracy and 
precision of the developed method was checked to assure the transfer of the 
method to this new matrix.  The %CV, representing precision ranged from 1-
10.3%, well within the permitted range.  Further the accuracy ranged from 85.7 to 
97.4%, indicating the method could accurately measure the concentration of 
rimonabant.   
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Rat Plasma Analysis 
 
The validated method was used to measure rimonabant in plasma samples 
from rats after intraperitoneal injection of rimonabant at the dose of 10 mg/kg. In 
the analyses, the frozen rat plasma samples and blank plasma were thawed to 
room temperature, 200 μl of plasma samples together with the blank plasma 
were prepared by the protein precipitation procedure described in Section 2.2.2 
and analyzed by the LC-MS-MS method.   
While there was no interference found in the untreated rat plasma (Figure 
2.15A), rimonabant was detected in rat plasma after both the 30 min and 12 h 
injection (Figures 2.15B and 2.15C).  Although the dose and the sampling times 
were not optimized to establish a pharmacokinetic study of this drug in the, the 
results demonstrate the applicability of the method for the measurement of 
rimonabant in plasma samples. Furthermore, the plasma concentration at 12 h 
after injection was higher than that at 30 min. This finding was consistent with the 
pharmacokinetic data in the US FDA briefing document (NDA 21-888, June 13,  
2007), which showed a mean half-life of ca. 16 days for the  drug in humans.   
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Figure 2.15, Mass chromatogram of (A) blank plasma, (B) animal treated for 
30 minutes, (C) animal treated for 12 hours and (D) the low calibrator (5 
ng/mL)
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Rat Brain Tissue Analysis 
 
This method, though not validated for the brain tissue matrix, was 
introductorily applied to samples.  In this analysis, the water in a volume of ten 5 
mL/gram of brain tissue was added to the whole rat brains.  The brain/water 
mixture was homogenized with an immersion blended.  Thereafter, 200 μL of the 
homogenized tissue solution was pipetted into centrifuge tubes, an amount of 
rimonabant calibration standard was added and the protein precipitation 
procedure described in section 2.2.2 was conducted.  Figure 2.16 shows a 
representative mass chromatogram for rimonabant extracted from a brain tissue 
solution. As evidenced in figure 2.16, rimonabant is clearly detectable when 
extracted from brain tissue.  No further investigation into the extraction, detection 
or validation of this method for the measurement of rimonabant in the brain 
matrix was conducted 
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Figure 2.16, Representative mass chromatogram of rimonabant extracted 
from brain tissue 
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100 
% 
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Canine Plasma Analysis 
 
 The canine samples, together with calibrators and controls were prepared 
as described in section 2.2.2.  As mentioned previously, there was no information 
provided regarding the dosing and time points for these samples.  Based on the 
lack of information provided, it is not possible to discuss the measurement of 
rimonabant in these samples.  However, the ability of the LC-MS-MS method to 
detect rimonabant in all samples which was expected to be found, speaks to the 
validity and applicability of this method in the research community.  The range of 
rimonabant concentrations detected in this study were from 20-125 ng/mL  A 
representative chromatogram of the low and high end of the concentrations 
detected, as well as the calibrator in this range, is contained in figure 2.17.   
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Figure 2.17, Representative mass chromatograms of rimonabant extracted 
from canine plasma with calculated concentrations of (A) 112 ng/mL, (B) 21 
ng/mL and (C) 100 ng/mL calibrator 
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2.2.4 Conclusion 
 
A rapid, sensitive HPLC-MS-MS bioanalytical method has been developed  
and validated for the measurement of rimonabant.  This method is able to 
effectively extract rimonabant from the matrices with suitable precision and 
recovery.  Further, the mass spectrometric detection of rimonabant enables an 
accurate measurement of analyte concentration.  Finally, the method has been 
successfully applied to a wide range of biological matrices, including, human 
plasma, rat plasma, rat brain tissue and canine plasma.  This method can be 
used in future pharmacokinetic and phamacodynamic studies.   
 
2.3  Development of a Quantitative Bioanalytical Method for the 
Measurement of Surinabant 
 
2.3.1  Introduction   
 
The development of the bioanalytical method to measure rimonabant was met  
with strong enthusiasm in the research community [38].  Within months of the 
manuscript being published, our research group was approached to conduct the 
analysis of a large scale animal study.  During this time, there was promising 
interest in the structurally similar CB antagonist, surinabant, as a therapeutic 
agent.  Due to the structural similarities of the compounds, it was expected that 
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the quantitative analytical method developed for rimonabant could be applied to 
the measurement of surinabant.   
Further, the results of the rimonabant canine study indicated that clinically 
relevant concentrations of the drug were in the 20-125 ng/mL range.  This 
concentration range suggested that there are a wide range of studies which find 
prove useful with a method employing a UV detector.  UV detectors are much 
less expensive, more widely available and easy to operate than a mass 
spectrometer.  Thus, a quantitative bioanalytical method using a UV detector was 
development for the measurement of surinabant.   
 
2.3.2  Materials and Methods 
 
Reagents 
 
Acetic acid, HPLC-grade acetonitrile, dimethyl sulfoxide (DMSO), formic acid, 
and 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-
pyrazole-3-carboxamide trifluoroacetate salt (AM251) were from Sigma-Aldrich 
(St. Louis, MO, USA).  Surinabant,   (5-(4-bromophenyl)-1-(2,4-dichloro-phenyl)-
4-ethyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide), was obtained from the drug 
repository (NIMH code S-908) of National Institute of Mental Health (Bethesda, 
MD, USA).  Pooled human plasma which contained no detectable surinabant 
was from Haemtech, Inc (Essex Junction, Vermont, USA). 
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A stock solution (1.00 mg/ml) of surinabant (C23H24Cl2N4BrO) was prepared 
by weighing 1.32 mg of the compound into a 1.5 ml Eppendorf tube (Eppendorf, 
Westbury, NY, USA) and thereafter, it was dissolved with 1.32 ml of DMSO.   A 
stock solution (1.00 mg/ml) of AM251 trifluoroacetate salt 
C22H21N4OCl2I·C2HF3O2) was prepared by weighing 1.18 mg of the compound 
into a 1.5 ml Eppendorf tube and dissolving it with 1.18 ml of DMSO.  Once the 
compounds had been dissolved in DMSO, both surinabant and AM251 stock 
solutions were transferred to 1.5 ml amber glass vials and stored at - 20 ºC when 
not in use.  
  A working solution (100 μg/ml) of surinabant was prepared by a dilution 
(1/10) of the surinabant stock solution with DMSO. A working solution (5.00 
μg/ml) of AM251 was prepared by a three-step dilution (1/8.3, 1/10, 1/2) of the 
AM251 trifluoroacetate salt stock solution with DMSO.  A mobile phase for liquid 
chromatographic separation was prepared by mixing 99.9% CH3OH/H2O (50:50, 
v/v) and 0.1% HCOOH.  The above solutions were stored at 4 C when not in 
use. 
 
 Calibrators and Controls 
 
Pooled human plasma containing no detectable surinabant was used as the 
blank plasma to prepare human plasma calibrators and controls for this study.  
Surinabant standard solutions (0.100, 0.1500, 0.200, 1.00, 1.50, 2.00, 5.00, 10.0, 
15.0, 20.0 and 30.0 μg/ml) were prepared by a serial dilution of the working 
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solution (100 μg/ml) with DMSO.   Surinabant plasma calibrators (5.00, 10.0, 
50.0, 100, 250, 500, 750, 1.00 x 103 and 1.50 x 103 ng/ml) were prepared by 
diluting the corresponding surinabant standard solutions in a 1:20 ratio with the 
blank plasma.  Surinabant plasma controls (7.50, 75.0, 150, 600, 750 and 1.20 x 
103 ng/ml) were prepared by a 1:20 dilution of the corresponding surinabant 
standard solutions with the blank plasma.  All plasma samples were stored at – 
20 C until use. 
 
 Surinabant Extraction from Plasma 
 
Plasma samples (e.g., surinabant plasma calibrators, surinabant plasma 
controls) were prepared using the following protocol.  First, 200 µl of plasma 
sample was pipetted into a 1.5 ml Eppendorf tube, then followed by 10.0 μl of the 
AM251 working solution (5.00 μg/ml) and 50.0 μl of acetic acid.  After vortex 
mixing, 1.00 ml of acetonitrile was added.  The solution was vortexed, then 
centrifuged at 13,000 g for 15 min.  After centrifugation, the supernatant was 
transferred to a 1.5 ml Eppendorf tube, and evaporated to dryness in a TurboVap 
LV Evaporator  (Caliper Life Sciences, Hopinkton, MA, USA) at 55 ºC with N2 
pressure of 20 psi for 2 h.  Prior to analysis, 200 µl of mobile phase was added to 
the dried samples. 
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Surinabant Recovery from Plasma 
The recovery of plasma surinabant by sample preparation procedure was 
determined using surinabant plasma controls and surinabant reference solutions 
at three different concentrations, which were 7.50, 75.0, 750 ng/ml for LC-ESI-
MS/MS and 150, 600 and 1.20 x 103 ng/ml for LC-UV.  The reference solutions 
contained the same sample matrix as that of plasma controls, which were 
prepared using blank plasma as samples by the same sample preparation 
procedure as that of plasma controls, and reconstituted in the mobile phase with 
appropriate surinabant concentrations.  
 
LC-UV Method 
 
Instrumentation:  A System Gold® HPLC BioEssential 126/128 from Beckman 
Coulter (Fullerton, CA, USA) was used in this work, which consisted of a126-
gradient pump, a 508-autosampler and cooler that was set at ambient 
temperature, a stainless steel in-line filter (0.5 μm  pore, 0.23 μL dead volume) 
from Upchurch Scientific (Oak Harbor, WA, USA), a YMCTM Pro C4 cartridge 
column (3 µm, 120 Å, 2.0 mm x 50 mm) from Waters (Milford, MA, USA), a 168-
photo diode array detector the was set at 258 nm, and a 32-karat workstation.  
The fluidic connection of the system was made using stainless steel tubing 
(0.0625 in. o.d., 0.0100 in. i.d.).  Data acquisition and peak integration was done 
by 32-karat software (version 8.0).  The peak area ratios of surinabant to the 
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internal standard were plotted against plasma surinabant concentrations for a 
calibration curve.   
Chromatographic separation: Surinabant and AM251 were separated under 
ambient temperatures on a Waters YMCTM Pro C4 cartridge column.  Prior to the 
analysis, the cartridge column was first equilibrated with the mobile phase 
containing 99.9% CH3OH/H2O (50:50, v/v) and 0.1% HCOOH at a flow rate of 
0.200 ml/min for about 30 min.  In each analysis, 20 μl of sample was injected 
with the autosampler, and the analytes were separated on the column by 
isocratic elution at a flow rate of 0.200 ml/min. 
 
LC-ESI-MS/MS Method 
 
Instrumentation: The LC-ESI-MS/MS system used in this work consisted of 
an HP1100 pump by Hewlett Packard (Palo Alto, CA, USA), an HP1100 
autosampler, a stainless steel in-line filter (0.5 μm pore, 0.23 μl dead volume) by 
Upchurch Scientific (Oak Harbor, WA, USA), a YMCTM Pro C4 cartridge column 
(3 µm, 120 Å, 2.0 mm x 50 mm) by Waters (Milford, MA, USA), a stainless steel 
splitting tee (1/16” x 0.25 mm) by Valco (Houston, TX, USA), and a Quattro II 
electrospray ionization triple quadrupole mass spectrometer by Micromass 
(Manchester, UK).  All fluidic connections of the system were made using high-
pressure polyether ether ketone (PEEK) tubing (0.0625 in. o.d., 0.0100 in. i.d.).  
The post-column split ratio was 1:2 with a smaller flow (ca. 63 μl/min) to the MS 
detector and the larger one to the waste.  Data acquisition and peak integration 
  126 
were accomplished using the Micromass Masslynx software (version 3.4).  The 
peak area ratios of surinabant to the internal standard were plotted against 
plasma surinabant concentrations for a calibration curve.   
Chromatographic separation:  The separation conditions were the same as 
those described in the Section 2.5. 
ESI-MS/MS detection:  The Micromass Quattro II triple quadrupole mass  
spectrometer was operated under the positive electrospray ionization mode 
(ESI+).  Tuning of the mass spectrometer was accomplished by infusion of a 
mixture of surinabant (2.0 μg/ml) and AM251 (2.0 μg/ml) in the mobile phase at a 
flow rate of 3 μl/min with a syringe pump (Harvard Apparatus, South Natick, MA, 
USA).  Ionization conditions were optimized as follows: nitrogen sheath and 
desolvation gas at 10 and 350 l/h, capillary at 3.5 kV, HV lens at 0.5 kV, cone at 
45 V, skimmer at 1.5 V, RF lens at 0.2 V, ion source temperature at 95 C, ion 
energy at 0.1 V, low- and high-mass resolution at 15, and multiplier at 700 V.  
Full-scan spectra were acquired in the continuum mode at a scan rate 400 u/s.  
Multiple reaction monitoring (MRM) mode was used for quantitation, which was 
set at the following conditions: m/z 523 → 423 for surinabant, m/z 555 → 455 for 
AM251, argon collision gas at 2.0-2.5 μbar, cone at 45 V, collision energy at 20 V 
for both analytes, low- and high-mass resolution at 10 for quadrupole 1 and 15 
for quadrupole 3, dwell time at 0.4 s, and the inter-scan delay at 0.01 s.  The 
ionization parameters were the same as those described previously.   
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2.3.3 Results and Discussion 
 
Calibrator and Control and Plasma Sample Preparation 
 
 When choosing a solvent for dissolution of analytes into a solution, there 
are two key considerations; first, the solvent chosen must dissolve the compound 
completely to produce a homogenous solution; secondly, the solvent should not 
cause matrix precipitation upon its addition to biological samples.   The chemical 
structures of both surinabant and AM251 indicates that they are hydrophobic 
compounds and are expected to have low solubilities in aqueous solution. 
Therefore, it will not be possible to dissolve either compound directly in biological 
samples.      
Our previous experiments with rimonabant showed that protonation of amine 
groups 0.1 M HCl had little effect on the water solubility of the compound.  Since 
surinabant has a similar structure with rimonabant which is completely soluble in 
DMSO and the addition of DMSO at 25% or lower does not cause protein 
precipitation in plasma [38], DMSO has been chosen as the solvent for the 
preparations of surinabant and AM251 stock and working solutions, as well as 
surinabant standard solutions.  The percent composition of DMSO in surinabant 
plasma calibrators and controls in this work was 10% (v/v) in which there was no 
protein precipitation observed.   
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Plasma samples were prepared by the protein precipitation procedure 
described in section 2.2.2.  The supernatant containing surinabant and AM251 
was evaporated to dryness in a TurboVap LV Evaporator.  The drying time may 
be shortened by increasing either the temperature of the water bath or the 
pressure of nitrogen flow.  The sample preparation procedure used has been 
proven by the recovery data (Table 1) to be adequate for the analysis of 
surinabant by LC-UV and LC-ESI-MS/MS methods. 
 
HPLC Method Using UV Detection 
 
In this work, a Waters YMCTM Pro C4 column was used based on the success 
of this column in the method developed for rimonabant.  Although surinabant has 
a smaller molecular weight than AM251, the presence of an ethyl group at the 4-
position of its pyrazole ring causes surinabant to be more hydrophobic than 
AM251.  The elution sequence from a C4 column was AM251 (7.4 min) first, then 
surinabant (9.4 min), and the total run time for each sample was about 11.0 min.  
Both surinabant and AM251 showed maximum absorptivity at 258 nm and no 
detectable interference from the blank human plasma was present in this range.  
Therefore, the signal at 258 nm was used for quantitation.    
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Figure 2.18, Chromatogram of surinabant (500 ng/mL) and AM251 (250 
ng/mL) 
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The recovery of surinabant was ascertained using the protein precipitation 
procedure and LC-UV method with surinabant plasma controls and surinabant 
reference solutions at three different concentrations (150, 600 and 1.2 x 103 
ng/mL).  The relative recoveries of surinabant were determined by comparing the 
mean-peak-area ratios of surinabant to the internal standard in the plasma 
controls to those of surinabant to the internal standard in the reference solutions.  
As discussed in section 2.2.3, the recovery should be consistent across the 
concentration range of interest.   
The precision of the LC-UV method was established by analyzing surinabant 
plasma controls at three different concentrations (150, 600 and 1.2 x 103 ng/mL) 
and was determined by the duplicate measurements of the peak-area ratio of 
surinabant to the internal standard from five separate samples at each 
concentration.  The ability of the LC-UV method to accurate measure the 
concentration of surinabant was also established using the low, middle and high 
concentrations used to determine precision.   The recovery, precision and 
accuracy of the LC-UV method is contained in table VII.   The data provided in 
this table indicates exceptional analytical performance of the LC-UV method to 
measure surinabant in human plasma.   
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Table VIII,  Analytical performance of the HPLC-UV method 
 
 
 
 
[Surinabant]
(ng/mL)
Recovery (%) Standard
Deviation
CV (%) Accuracy (%)
150 103% 0.0099 3.0% 87%
600 95.0% 0.0535 3.9% 97%
1.20 x 103 97.0% 0.0857 3.1% 93%
All determinations were based on the mean value obtained from five (5) separate samples at
each concentration.  The concentration of internal standard was fixed  (250 ng/mL)
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The linear response of the LC-UV method was determined by plotting the 
internal standard corrected surinabant peak-area versus the concentration of 
surinabant calibrator.  A linear calibration range of 100-1500 ng/ml with a 
correlation coefficient of 0.999 was achieved.  A calibration equation, y = 
0.00232x – 0.0619, was derived from the average peak area ratio of two 
separate injections from a single sample at each of the six concentrations (100, 
250, 500, 750, 1000 and 1500 ng/ml) over the calibration range.  A second 
condition which was not discussed in section 2.2.3 for the identification of the 
lower limit of quantification (LLOQ) suggested by the FDA guidelines is that the 
precision and accuracy of this measurement fall within a 20% error range.  The 
LLOQ of the LC-UV method was determined by the lowest plasma surinabant 
calibrator on the calibration curve to be 100 ng/ml with a CV and an accuracy of 
8.0 and 95.0%, respectively.     
 
HPLC Method with Mass Spectrometric Detection 
 
In the LC-ESI-MS/MS method, the chromatographic separation conditions 
were the same as those described in the LC-UV method.  However, because the 
fluidic connection of this system included a post column splitter, the elution times 
of AM251 and surinabant were slightly longer than (ca. 0.9 min) those of the LC-
UV method.  A post-column splitter is required to divert a portion of the sample 
flow to waste; thereby assuring that the flow rate entering the MS is under the 
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100 μL/min discussed in section 1.5.2.    The total run time for each sample was 
approximately 12.0 min.   
The full-scan mass spectra by positive electrospray ionization revealed 
that surinabant and AM251 produced predominant protonated molecular ions at 
m/z 523 and 555, respectively.  These parent ions were fragmented to produce 
daughter mass spectra which resulted in predominant product ions at m/z 423 for 
surinabant and m/z 455 for AM251.   
As with the method for rimonabant, these product ions were measured by 
the multiple-reaction-monitoring (MRM) mode for internal calibration and 
quantitation of surinabant.  The selectivity and specificity of the LC-ESI-MS/MS 
method by MRM mode for the measurement of surinabant and AM251 is 
illustrated by the mass chromatograms contained in figure 2.20 which show no 
interference from the plasma matrices.  
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Figure 2.19. (A) Full scan of surinabant, (B) daughter ions of surinabant, (C) 
full scan of AM251 and (D) daughter ions of AM251 
 
(A) 
(B) 
(D) 
(C) 
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Figure 2.20, Representative mass chromatograms of surinabant and AM251 
in (A) blank plasma, (B) plasma treated with AM251 (250 ng/mL) only and (C) 
plasma treated with both surinabant (500 ng/mL) and AM251 (250 ng/mL) 
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The fragmentation of surinabant produced a predominant product ion of 100 
amu less than its parent ion, a pattern identical to that rimonabant and AM251 
described in our previous work.  Therefore, the fragmentation reaction of 
surinabant could be proposed and is contained in figure 2.21. 
The recovery of surinabant was established using the protein precipitation 
procedure and LC-ESI-MS/MS method previously described with surinabant 
plasma controls and surinabant reference solutions at three different 
concentrations (7.50, 75.0 and 750 ng/ml).  The precision (%CV) and accuracy 
was determined by the triplicate measurements of the peak area ratio of 
surinabant to the internal standard from five separate samples at each of the 
three concentrations listed above.  The method for calculating for these 
parameters has been previously discussed.   The recovery, precision and 
accuracy values are reported in Table VIII. 
The linear calibration range of the LC-ESI-MS/MS method was 5.00 to 
1000 ng/ml with a correlation coefficient of 0.999.  A calibration equation, y = 
0.00373x – 0.00941, was derived from the average peak area ratio of three 
separate injections from a single sample at each of the six concentrations (5.00, 
10.0, 50.0, 100, 500 and 1000 ng/ml) over the calibration range.  The LLOQ for 
the LC-ESI-MS/MS method was determined to be 5.00 ng/ml with a CV and an 
accuracy of 6.0 and 90.9%, respectively.     
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Figure 2.21, Proposed fragmentation scheme of surinabant  
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Table IX, Analytical performance of HPLC-MS method 
 
 
 
  
[Surinabant] 
(ng/mL)
Recovery (%) Standard 
Deviation
CV (%) Accuracy (%)
7.50 101% 2.60 x 10-3 7.7% 92%
75.0 96.0% 0.009 2.9% 87%
750 100% 0.145 5.7% 93%
All determinations were based on the mean value obtained from five (5) separate samples t 
each concentration.  The concentration of internal standard was fixed  (250 ng/mL)
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Surinabant Stability 
 
The stability of surinabant in plasma was established by three aliquots at 
each low and high controls.  As with rimonabant, all error reported refers to the 
difference between the condition the sample was exposed to and time zero.   
After three freeze (−20 C) and thaw (room temperature) cycles, a maximum 
relative error of 6% was observed.  The short-term temperature stability of 
surinabant in plasma was established by storing the surinabant plasma controls 
at room temperature for 24 h with the maximum relative error observed being 
4%.  A study was conducted to determine the necessity of storing surinabant 
samples in amber vials to protect the compound from light degradation.  
Surinabant plasma controls stored in amber versus clear vials for six weeks at -
20 C gave a maximum relative error of 7% which showed that surinabant could 
be stored safely under these conditions without protection from light.  Overall, in 
all situations investigated, surinabant exhibits sufficient stability.   
 
2.3.4  Conclusion 
 
Two methods, an LC-UV and an LC-ESI+-MS/MS method have been 
developed and validated for the quantitative measurement of surinabant in 
human plasma using AM251 as the internal standard.  A protein precipitation 
procedure using acetonitrile was established, which resulted in consistent 
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recovery of surinabant.  A LLOQ of 100 ng/ml and a calibration range of 100-
1500 ng/ml was obtained for surinabant.  LC-ESI-MS/MS detection had a LLOQ 
of 5.00 ng/ml and a calibration curve of 5.00-1000 ng/ml for surinabant.   Both 
methods developed exhibited strong analytical performance which is validated by 
the recovery, precision and accuracy of the methods to measure surinabant.   
The low limits of detection achieved with these methods permits their application 
to a variety of studies involving the pharmacology, toxicology and biochemical 
mechanisms of surinabant.   
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CHAPTER III 
 
 
PRELIMINARY WORK CONDUCTED TO DEVELOP 
BIOANALYTICAL METHODS FOR THE MEASUREMENT OF ANTI-CANCER 
AGENTS, QUINACRINE AND TRIAPINE 
 
 
 
 
3.1  Quinacrine 
 
3.1.1 Introduction 
 
Quinacrine is a drug with a long history and broad, interesting therapeutic 
applications.   The chemical structure of quinacrine is contained in figure 3.1.   It 
was first used in the 1930‟s as an antimalarial compound [1].  Over the years it 
has also been used to treat infections of the parasite Giardia [2].  
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Figure 3.1, Chemical structure of quinacrine 
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A controversial, but common use of quinacrine is to cause female sterilization; 
primarily in poor, underdeveloped and overpopulated areas [3].  Quinacrine has 
also offered hope for the currently, untreatable, condition of prion disease [4].  
Finally, quinacrine has shown promise as an anti-cancer agent [5].  The recent 
interest in the use of quinacrine for the treatment of both prion disease and 
cancer resulted in an anticipated need for a bioanalytical method to measure this 
compound, which led to the preliminary steps presented in this work.   
The role of quinacrine in the treatment of cancer revolves around its ability to 
inhibit tumor protein 53 (p53) [6].  P53 is transcription factor which is present on 
both tumor and non-tumor cells.  In tumor cells, p53 is generally inactivated.  
Therefore, typical cancer therapy‟s cause tumor cells die via non-apoptotic 
processes.  On the contrary, normal tissues undergo a high rate of apoptosis 
during cancer treatment which is responsible for the deteriorative, adverse side 
effects.  Research has shown that quinacrine can serve as a p53 activator, 
thereby re-establishing the ability of tumor cells to undergo apoptosis [6] [7].  In 
this sense, quinacrine is able to sensitize the tumor cells to an increased death 
rate of these cells. 
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Figure 3.2, Block diagram describing the role of quinacrine in cancer 
treatment 
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There is no current pharmacological treatment for prion disease; a severe, 
progressive, neurological disorder.  Prion disease is caused by the propagation 
of a misfolded prion protein, PrP.  PrPSC is the isoform of PrP which is indicated 
in prion disease.  PrPSC converts the structure PrP to the infectious PrP
SC  form.  
Quinacrine is able to block the conversion of PrP to PrPSC in vitro [8].  It should 
be mentioned that neither the mechanism involved in the structural change from 
PrP to PrPSC, nor quinacrines ability to inhibit it; is well understood.   
 In 2004 research was published which established an HPLC-MS/MS 
method for the measurement of quinacrine [9].  The research described paints an 
initial pharmacokinetic profile of quinacrine as it relates to the treatment of prion 
disease.  The study published in this article provides a strong stepping stone for 
the measurement of this compound.  However, the work was lacking many 
features which are critical to demonstrating the performance of a quantitative 
bioanalytical method.  Notably, there lacked a discussion regarding the sample 
extraction methods and validation of the ability of the method to measure 
quinacrine.   
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3.1.2  Materials and Methods 
 
Reagents 
 
Acetic acid, HPLC-grade acetonitrile and methanol, dimethyl sulfoxide 
(DMSO), and formic acid, ammonium acetate and quinacrine were purchased 
from Sigma-Aldrich (St. Louis, MO, USA).  The internal standard, NCI number 
10593-V/2 was provided, at no cost, by National Cancer Institute Drug 
Depository  
The quinacrine stock solution (1.00 mg/ml) was prepared by weighing 0.85 
mg of the compound into a 1.5 ml Eppendorf tube (Eppendorf, Westbury, NY, 
USA) and dissolving it with 0.85 ml of MeOH:H2O (50:50 v/v). A stock solution 
(1.00 mg/ml) of 10593-V/2 was prepared by weighing 1.20 mg of the compound 
into a 1.5 mL Eppendorf tube and dissolving it with 1.20 ml of MeOH:H2O (50:50 
v/v). 
Once the compounds were dissolved, both quinacrine and the internal 
standard stock solutions were transferred to 1.5 ml amber glass autosampler 
vials, sealed with parafilm, and were stored at - 20 ºC when not in use.  
Quinacrine and internal standard working solutions (100 μg/ml) was prepared by 
a dilution (1/10) of the stock solution with MeOH:H2O (50:50 v/v). A mobile phase 
for liquid chromatographic separation was prepared by first adding ammonium 
acetate to water.  The ammonium acetate/H2O solution was mixed with methanol 
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(50% v/v) with the ammonium acetate concentration being 5mM of the final 
mobile phase volume.  All solutions were stored at 4◦C when not in use. 
 
Instrumental Setup 
 
The instrumental setup used in this work consisted of an HP1100 pump by 
Hewlett Packard (Palo Alto, CA, USA), an HP1100 autosampler, a stainless steel 
in-line filter (0.5 μm pore, 0.23 μl dead volume) by Upchurch Scientific (Oak 
Harbor, WA, USA), a Oasis HLB  cartridge column (2.1 mm x 20 mm) by Waters 
(Milford, MA, USA), and a HCT ion trap mass spectrometer by Bruker Daltronics 
(Billerica, MA, USA). All fluidic connections in the system were made using high-
pressure polyether ether ketone (PEEK) tubing (0.0625 in. o.d., 0.0100 in. i.d.).  
 
HPLC Separation 
 
Analytical separation was performed via a Oasis HLB  cartridge column (3 
μm, 120 Å, 2.0 mm x 50 mm) by Waters (Milford, MA, USA). Before analysis, the 
cartridge column was equilibrated with mobile phase at a flow rate of 0.100 
ml/min for about 20 min. During the analyses, 20 μl of sample was injected by the 
autosampler and carried onto the cartridge column by the mobile phase at a flow 
rate of 0.100 ml/min.  Under the conditions described above, quinacrine and the 
internal standard had a retention times of 3.5 and 3.8 minutes, respectively.   
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  MS Detector Settings 
 
A Bruker HCT ion trap mass spectrometer was used for the detection of 
quinacrine and the internal standard, 10953-V/2.  The IT-MS parameters used 
were as follows:  positive polarity, a capillary voltage of -4500 V, nebulizer gas 
pressure of 35 psi, drying gas flow or 9.0 L/min, a drying gas temperature of 
340°C, and a fragmentation amplitude of 0.6V.  The IT-MS was operated in ultra 
scan mode to provide optimum resolution and sensitivity.   
 
3.1.3  Discussion 
 
 The focus of the work here was primarily to determine whether an on-line 
sample extraction would be possible for the measurement of quinacrine in 
biological matrices.  As discussed in Chapters I and II, on-line sample extraction 
has many advantages over traditional, LLE, protein precipitation and SPE 
procedures.     
 The development of an HPLC separation method was investigated using a 
Waters Oasis HLB column.  An IT-MS was used for the detection of quinacrine 
and the internal standard.  The internal standard, identified as 10593-V/2, was 
provided by the National Cancer Institute Drug Repository Program, the chemical 
structure is contained in figure 3.3.  
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Mass Spectrometric Detection 
 
As evidenced by the chemical structure of quinacrine, there are several 
nitrogen groups which may be protonated.  When a compound exists in several 
ionic forms, the mass spectrometric sensitivity can be compromised.  As 
discussed in Chapter I, the MS detector reports a signal based on the m/z ratio of 
the analyte.  Multiple charged species result in several m/z ratios being attributed 
to a single analyte mass.  When conducting quantitation using MRM mode, only 
one m/z ratio is selected to undergo isolation and fragmentation.  As predicted by 
the chemical structure, a full scan of quinacrine revealed the presence of two 
molecular ions; the singly protonated ion at m/z 400 and the doubly protonated 
species at m/z 200.6 (figure 3.4).  
The solvent used to dissolve quinacrine which resulted in the spectra 
contained in figure 3.4 was a 50:50 mixture of MeOH:H2O, 0.3% formic acid, pH 
4.0.  In order to preferentially select for the singly protonated form of quinacrine, 
several mobile phase compositions were tested.  The solvent chosen to dissolve 
quinacrine was 50:50 mixture of MeOH:H2O, 5mM ammonium acetate, pH 5.8.  
Figure 3.5 contains the full scan spectra of the predominantly singly protonated 
ions of quinacrine and the internal standard
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Figure 3.3, Chemical structure of 10593-V/2 
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Figure 3.4, Full scan spectra of quinacrine 
 
  
200.6 
400.2 
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
6 x10 Intens. 
150 200 250 300 350 400 m/z 
  157 
 
 
 
 
Figure 3.5, Full scan spectra of (A) quinacrine and (B) 10593-V/2, the internal 
standard 
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Daughter ion spectra of quinacrine and the internal standard are contained in 
figure 3.6.  The fragments selected for the detection of quinacrine and the 
internal standard in subsequent analysis were m/z 244 for quinacrine and m/z 
403 for 10593-V/2, the internal standard.   
Mass chromatograms for quinacrine and the internal standard are exhibited  
in figure 3.7.  Using the HPLC-MS parameters discussed, a calibration curve was 
obtained for quinacrine standards with the linear range of 50 – 2000 ng/mL and a 
correlation coefficient of 0.999.   
 
Analyte Extraction via On-line Sample Extraction 
 
The Waters Oasis HLB is marketed for its ability to work well in the design  
an on-line extraction procedure.  In this case, the idea is that plasma containing 
quinacrine can be directly injected onto the column; quinacrine would be retained 
by the column, while the plasma proteins and other matrix components would 
travel to waste.  This is accomplished by using a column switch to alternate 
between the column elutent flowing to waste or to the mass spectrometer.  A flow 
diagram of the set up of one example of a fluidic profile tested is contained in 
figure 3.8.   
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Figure 3.6 Daughter ion spectra of (A) quinacrine and (B) 10593-V/2, the 
internal standard 
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Figure 3.7, Mass chromatograms of (A) quinacrine and (B) 10593-V/2 
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As evidenced in figure 3.8, initially the aqueous mobile phase flows at 200 
μL/min for 1.0 minutes to load the sample onto the column.  Next, the flow is kept 
constant and a mobile phase with a 50% organic composition is introduced to the 
column.  During this step, quinacrine is retained by the column while the matrix 
components are diverted to waste.  Thirdly, the column switch changes the flow 
so that the column elutent is able to travel to the MS detector.  It is during this 
time that the analyte is eluted from the column and subsequently detected.  The 
next two steps involve regenerating the aqueous solvent through the column at a 
high flow rate and finally, reducing the flow of the aqueous solvent to allow for 
pressure equilibration.  
Quinacrine is a hydrophobic compound which resulted in it being retained so 
strongly by the HLB column that a high degree of carryover occurred between 
analyses.  The carryover dilemma resulted in the feasibility of on-line extraction 
being abandoned.  Without the development of an on-line extraction procedure, 
the further investigation into developing a quantitative bioanalytical method for 
quinacrine was not warranted.   
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Figure 3.8, Fluidic profile for on-line sample extraction of quinacrine 
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3.2  Triapine 
 
3.2.1  Introduction 
 
Triapine (3-AP) is a relatively new compound being investigated for use as an  
anti-cancer therapy [10].  The chemical structure of 3-AP is contained in figure 
3.9.  Vion Pharmaceuticals is developing 3-AP which is currently in both Phase I 
[11] [12] [13] and II [14] clinical trials.    
Cancer is caused by the uncontrolled proliferation of tumor cells.  
Ribonucleotide reductase (RNR) is an enzyme which affects cellular proliferation 
both by catalyzing the transformation of ribonucleotides (NTP‟s) to 
deoxyribonucleotides (dNTP‟s), the building blocks of DNA; as well as by 
involvement in the DNA repair process [15].   3-AP belongs to a class of 
compounds referred to as RNR inhibitors [16].   
The ability of 3-AP to inhibit the conversion of NTP‟s to dNTP‟s effectively 
halts cellular proliferation and thus, the development of tumors.  It has been 
reported that the ability of 3-AP to inhibit RNR lies in the metal chelating 
properties of 3-AP [15].  Chelation involves the ability to a ligand such as 3-AP to 
form complexes with metal ions.  
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Figure 3.9, Chemical structure of 3-AP 
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Figure 3.10, Role of triapine in cellular proliferation 
 
DNA 
synthesis
cell 
proliferation
tumor growth
DNA 
repair
D
N
A
 
d
a
m
a
g
e
c
e
ll
 
p
ro
li
fe
ra
ti
o
n
triapine
nucleotide
DNA
damaged 
DNA
D
N
A
 
d
a
m
a
g
e
c
e
ll
 
p
ro
li
fe
ra
ti
o
n
  166 
  
 RNR is an iron dependant enzyme which catalyzes the reaction of NTP‟s 
to dNTP‟s via a free radical reaction.  This reaction occurs at the active site of the 
protein molecule which contains an iron, essential to the enzyme function.    It 
has been suggested that the ability of triapine to inhibit this process is related to 
3-APs involvement with the iron in the active site of RNR.   
As mentioned, 3-AP is a new cancer treatment which is the subject of heavy 
clinical investigation.  Currently there are no publicly available bioanalytical 
methods for the measurement of 3-AP.  Thus, the development of such method 
is of strong importance.    The scope of this work encompasses:  the preliminary 
data obtained for the detection of triapine using HPLC-MS methods; the 
challenges faced; and suggestions for the future development of this method.  
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Figure 3.11, 3-AP as it relates to the conversion of NTP‟s to dNTP‟s  
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3.2.2  Materials and Methods 
 
Reagents 
 
Acetic acid, HPLC-grade acetonitrile, dimethyl sulfoxide (DMSO), and formic 
acid, were purchased from Sigma-Aldrich (St. Louis, MO, USA).  3-
aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine or 3-AP) was 
provided, at no cost, by Vion Phamaceuticals (New Haven, CT, USA).  
Thioacetazone, the internal standard, was provided at no cost from the National 
Cancer Institute Drug Depository (NCI reference #3550).   
The 3-AP stock solution (1.00 mg/ml) was prepared by weighing 1.28 mg of 
the compound into a 1.5 ml Eppendorf tube (Eppendorf, Westbury, NY, USA) 
and dissolving it with 1.28ml of solvent (either DMSO or a MeOH:H2O mixure). A 
stock solution (1.00 mg/ml) of thioacetazone was prepared by weighing 1.45 mg 
of the compound into a 1.5 mL Eppendorf tube and dissolving it with 1.45 ml of 
solvent.  
Once the compounds were dissolved, both 3-AP and internal standard stock 
solutions were transferred to 1.5 ml amber glass autosampler vials, sealed with 
parafilm, and were stored at - 20 ºC when not in use.  3-AP  working solutions 
(100 μg/ml) was prepared by a dilution (1/10) of the 3-AP stock solution with 
solvent. A mobile phase for liquid chromatographic separation was prepared by 
first adding formic acid (HCOOH) to water.  The formic acid/H2O solution was 
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mixed with methanol (35% v/v) with the HCOOH concentration being 0.1% of the 
final mobile phase volume.  All solutions were stored at 4◦C when not in use. 
 
Instrumental Setup 
 
The instrumental setup used in this work consisted of an HP1100 pump by 
Hewlett Packard (Palo Alto, CA, USA), an HP1100 autosampler, a stainless steel 
in-line filter (0.5 μm pore, 0.23 μl dead volume) by Upchurch Scientific (Oak 
Harbor, WA, USA), a YMC™Pro C18  cartridge column (3 μm, 120 Å, 2.0 mm x 
50 mm) and YMC™Pro C18AQ cartridge column column (3 μm, 120 Å, 2.0 mm x 
50 mm)  by Waters (Milford, MA, USA), a stainless steel splitting tee (1/16” x 0.25 
mm) by Valco (Houston, TX, USA), and a Quattro II triple quadrupole mass 
spectrometer by Micromass (Manchester, UK). All fluidic connections in the 
system were made using high-pressure polyether ether ketone (PEEK) tubing 
(0.0625 in. o.d., 0.0100 in. i.d.). The post-column split ratio was 1:2 with a smaller 
flow (ca. 63 μl/min) to the MS detector and the larger one to the waste. 
 
HPLC Separation 
 
Analytical separation was performed via a Waters YMC™Pro C18  or 
YMC™Pro C18AQ cartridge column. Before analysis, the cartridge column was 
equilibrated with  mobile phase at a flow rate of 0.100 ml/min for about 20 min. 
During the analyses, 20 μl of sample was injected by the autosampler and 
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carried onto the cartridge column by the mobile phase at a flow rate of 0.200 
ml/min.  Under the conditions described above, 3-AP had a retention time of 2.75 
minutes.   
 
  MS Detector Settings 
 
Electrospray ionization mode (ESI+) was utilized on the Micromass Quattro II 
triple quadrupole mass spectrometer. Tuning of the mass spectrometer was 
achieved by infusion of a 3-AP (10.0 μg/ml) in the mobile phase at a flow rate of 
3.0 μl/min with a syringe pump (Harvard Apparatus, South Natick, MA, USA). 
Optimal ionization conditions were as follows: nitrogen sheath and desolvation 
gas at 10 and 350 l/h, capillary at 3.5 kV, HV lens at 0.5 kV, cone at 30 V, 
skimmer at 1.5 V, RF lens at 0.2 V, ion source temperature at 80◦C, ion energy at 
1.0 V, low- and high-mass resolution at 10, and multiplier at 700 V. Full-scan 
spectra were acquired in the continuum mode at a scan rate 400 u/s.  The 
instrument was operated in multiple reaction monitoring (MRM) mode for 
quantitation, which was set as follows: m/z 196 → 94 and 196 → 120  for 3-AP, 
argon collision gas at 2.0-2.5 μbar, cone at 30 V, collision energy at 30 V, low- 
and high-mass resolution at 10 for quadrupole 1 and 10 for quadrupole 3, dwell 
time at 0.4 s, and the inter-scan delay at 0.01 s. The parameters for ionization 
remained the same as previously discussed.   
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3.2.3  Discussion 
 
Sample Preparation 
 
As discussed 3-AP is a metal chelator, therefore precautions should be taken  
to avoid the introduction of metals to the analyte when preparing stock solutions.  
A wooden or plastic was employed for the removal and weighing of 3-AP, but the 
challenge remains to reduce the contact of 3-AP with metal ions throughout 
sample preparation and analysis.  
 A common approach to avoid unwanted interactions of an analyte that is a 
metal chelator is the use of a stronger chelator, such as 
ethylenediaminetetraacetic acid (EDTA).  EDTA can be added to stock solutions 
and mobile phases in order to preferentially bind with any metals, thus leaving 3-
AP unreacted and detectable.  In the case of HPLC-UV methods, EDTA is a 
common additive and has little effect of the sensitivity of the method.  However, 
in HPLC-MS, the detection of analyte is depending on ionization, as discussed in 
Chapter 1.   
 The use of any additive in mass spectrometry, including EDTA; can 
negatively impact the sensitivity of the method based on the ion suppression 
theory.  Ion suppression is a type of matrix effect caused when there is an 
excess of ionizable molecules eluted from the HPLC system concurrently with 
the analyte molecules.  A graphical representation of ion suppression is 
contained in figure 3.12.   
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Figure 3.12, (A) ideal ionization versus (B) ion suppression 
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To understand ion suppression, it is helpful to consider that at during any 
given timeframe, there only exists enough electrical current to ionize a fixed 
amount of molecules.  In figure 3.12(A) which represents ideal ionization, the 
entire electrical field is able to be applied to the analyte, depicted in red.  
However, if elution from the HPLC results in matrix components present during 
the ionization of the analyte, only a fraction of the molecules ionized and 
thereafter detected, will be analyte molecules.  In this sense, ion suppression 
diminishes the sensitivity of the method being developed.   
The suppression is exasperated in any matrix component which is more 
easily ionized than the analyte molecules, which is often the case when EDTA is 
used.  Therefore, if EDTA is employed as an additive, consideration must be 
taken to determine the ratio between the amounts which are beneficial versus the 
amount which causes detriment to the detection of the analyte.   
A final aspect of 3-AP sample preparation is the ability of the compound to 
dissolve.  As expected from the chemical structure, 3-AP is not water soluble.  
Further 3-AP has a pKa of 4.2 which indicates that it will exist in a protonated 
form at a pH less than 4.2.  Several solvent compositions were tested for their 
ability to dissolve 3-AP.  DMSO readily dissolves the compound; however, in 
order to achieve control of the pH, the solvent composition should have an 
aqueous component.  Both 50% DMSO and 50% MeOH in H2O, adjusted to pH 
4.0 with formic acid are able to dissolve 3-AP.  It is important to note that the 
addition of an acidic component to the solvent causes a dramatic increase (10 
fold) in the bright yellow color observed.   
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Mass Spectrometric Detection 
 
The first step in the development of an HPLC-MS method is to optimize the  
ionization, fragmentation and detection parameters of the MS instrument.  This 
process was undertaken by infusion of 10 μg/mL of the analyte dissolved in a 
solution of 50% MeOH in H2O, adjusted to a pH of 4.0.  Figure 3.13 contains the 
full scan and daughter ion spectra for 3-AP.  The instrument used for the 
detection of 3-AP was a Quattro II triple quadrupole mass spectrometer by 
Micromass.   
As evident in figure 3.13(A), the predominant analyte ion is present at the m/z 
of 196, which represents the singly protonated 3-AP molecule.   Fragmentation of 
the ion at m/z of 196 results in two predominant daughter peaks; m/z 94 and m/z 
of 120.  The ratio of daughter peaks is variable depending primarily upon the 
collision gas pressure.   
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Figure 3.13, (A) full scan, and (B) daughter spectra of 3-AP 
 
   
  
60 80 100 120 140 160 180 200 220
m/z0
100
%
0
100
%
(A)
(B)
m/z 196
m/z 94
m/z 120
  176 
Figure 3.14 contains mass chromatograms of the total ion signal due to the 
ion with the m/z ratio of 196, and the extracted signal of the daughter ions at both 
m/z 94 and 120.  It is evident in this figure that a significant portion of the total 
signal is due to the signal of both daughter ions.  These mass chromatograms 
were obtained using the following HPLC parameters:  a Waters YMC Pro C18 
column; a mobile phase composition of 35% MeOH in H2O adjusted to a pH of 
4.0 with formic acid; a flow rate of 100 μL/min with a post column splitter diverting 
2/3rds of the flow to waste.   
Figure 3.15 contains mass chromatograms of stock solutions of 3-AP ranging 
from1.00 ng/mL to 100 ng/mL.  For the purpose of the current clinical 
investigations, it is expected that a detection limit in the range of 1 ng/mL will be 
required to precisely and accurately measure 3-AP in human plasma.  As 
evidenced by this figure, the sensitivity achieved with efforts to date, are not 
sufficient to continue forward with steps to develop a procedure for extraction of 
3-AP from a plasma matrix.    
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Figure 3.14, Extracted ion chromatogram for 3-AP of (A) daughter ion m/z 94, 
(B) daughter ion m/z 120 and (C) the total ion chromatogram of 3-AP which 
(A) and (B) were extracted from 
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Figure 3.15, Mass chromatograms at 3-AP from 1.00 to 100 ng/mL 
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3.2.4  Challenges and Future Direction for The Development of a Quantitative 
Bioanalytical Method to Measure 3-AP 
 
 The challenges faced during the preliminary development of a 
bioanalytical method for the measurement of 3-AP were centered on two major 
hurdles:  first, the nature of 3-AP as a metal chelator; and secondly, the apparent 
resistance of 3-AP to electrospray ionization.  
 
 Metal Chelation 
  
 As discussed, 3-AP is a metal chelator and the current approach to 
analysis of this compound requires that it remain in a non-chelated, free form.  
While the introduction of metal ions can be avoided in many respects, the design 
of modern instruments involves a substantial amount of metal components.  The 
interaction with the analyte cannot be avoided in these instances.   
 One solution to the metal chelation challenge is to employ the use of 
stronger chelating compounds in the preparation of stock solutions and mobile 
phases.  EDTA is one such compound, but its use is a “double-edged sword”; the 
benefits afforded by its chelating power may be outweighed by the ion 
suppression it causes.  
 The first step in overcoming any challenge that metal chelation poses in 
the development of this method would be to conduct a systematic study using 
EDTA as an additive at varying ratios to 3-AP.  Further, alternative chelating 
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agents such as nitrilioacetic acid (NTA) may be investigated as superior 
substitutes to EDTA.    
 
Ionization 
 
It is not possible to develop a successful quantitative bioanalytical method 
using HPLC-MS without ionizing the compound to be analyzed.  Great detail was 
provided in Chapter I regarding the importance of ionization and the various ion 
sources commercially available.  Often the chemistry of a compound leaves it 
resistant to the acceptance (or loss of) a proton.  Additionally, it is not uncommon 
for a compound to undergo substantial fragmentation during the ionization 
process.   
 In the case of 3-AP, the resistance of the compound to protonation should 
be investigated.  As previously discussed, 3-AP has a pKa of 4.2, and the 
dissolution of the compound in acidic solutions generates a strong color change.   
It is possible that once triapine undergoes the initial protonation in the dissolution 
process, that the resulting chemical structure is stabilized in a neutral form and 
that the normal ESI process is unable to protonate the analyte further.  In this 
case, it should be investigated whether the acidic conditions during sample 
preparation are required for 3-AP to dissolve.   
 In some instances; it is not a chemical resistance to protonation which 
causes a lack of ions for analysis, but a disintegration of the analyte material 
during ionization.  As described in Chapter I, the ESI process can be enhanced 
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through the introduction of a nebulizing gas such as nitrogen.  The pressure of 
this nebulizing gas is a parameter which should be optimized to achieve 
maximum ionization.   
However, it is not only the gas pressure which can prematurely fragment and 
render an analyte undetectable.  In some situations, the chemical structure of a 
compound is such that the desolvation process itself creates instability and 
results in unwanted fragmentation.  Typically, ESI is the ionization process of 
choice due to the balance between its gentle yet powerful mechanism.  For 3-AP, 
it would be useful to investigate the benefit of an alternate, even softer ionization 
source such as APCI.   
 
Conclusion 
 
Mass spectrometry is one of the most sensitive detection methods available 
to the analytical chemist.  It is impossible to establish the underlying cause for 
the inability of this technique to perform in the detection ranges expected with the 
experiments‟ conducted with 3-AP to date.  Two directions have been proposed 
to increase the detection ability of the mass spectrometer for this compound.  
Overall success may not come from taking just one route and may involve a 
modulation of both.   
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